

## CURRICULUM VITAE

**Brian R. Ott, M.D.**

Business Address: Neurology Department  
Rhode Island Hospital – APC 7  
593 Eddy Street  
Providence, RI 02903

Business Telephone: (401) 444-5745  
FAX: (401) 606-8555  
E-Mail: Brian\_Ott@brown.edu

### EDUCATION:

Undergraduate: Syracuse University, Syracuse, NY, Biology, *BS*  
1971-1975

Medical School: Jefferson Medical College, Philadelphia, PA, Medicine, *MD*  
1975-1979

Other degrees: Brown University, Providence, RI, *MA, ad eundem*  
2015

### POSTGRADUATE TRAINING:

Internship: Internal Medicine, Roger Williams General Hospital,  
1979-1980 Brown University School of Medicine, Providence, RI

Residency: Internal Medicine, Roger Williams General Hospital,  
1980-1982 Brown University School of Medicine, Providence, RI

Residency: Neurology, Longwood Program: Brigham and Women's, Beth Israel, Children's,  
1982-1985 and V.A. Hospitals, Harvard University Medical School, Boston, MA

### AWARDS AND HONORS:

1975 Syracuse University, Phi Beta Kappa, Magna Cum Laude  
1979 Arthur Krieger Memorial Prize in Neurology, Jefferson Medical College  
1987 Greater Boston Physicians for Social Responsibility Code Blue Award, Co-recipient  
1990 Fellowship, American College of Physicians  
1991 Surdna Foundation Fellowship, Brown University Center for Gerontology and Health  
Care Research  
1998 Membership, American Neurological Association  
1998 Fellowship, American Academy of Neurology  
1999 Honorary Brian Ott Annual Alzheimer Research Symposium founded by the RI Chapter,  
Alzheimer's Association; recognized by Lieutenant Governor's Office, State of RI  
1999 Excellence in Teaching Award, Brown University Geriatric Psychiatry Program  
2002 Who's Who in Medicine and Healthcare, 4<sup>th</sup> edition  
2003 Who's Who in America, 58<sup>th</sup> edition  
2004 Best Doctors in America, Neurology

2011	Adjunct Professor of Pharmacy Practice, University of Rhode Island
2013	Appointment by Governor Lincoln Chafee to the Rhode Island Advisory Commission on Aging
2013	Fellowship, American Neurological Association
2013	Jerome Ely Award for article of the year, <i>Human Factors</i>
2014	Dean's Excellence in Teaching Award, Alpert Medical School of Brown University
2017	Adjunct Professor of Neuroscience, University of Rhode Island
2018	Positive Champion of the Learning Environment, Alpert Medical School, Brown University
2018	Visiting Professor, Southern Illinois University
2018	Elise M. Coletta Education Leadership Award, Rhode Island Chapter, American Academy of Family Physicians
2018	Milton Hamolsky Lifetime Achievement Award, Rhode Island Chapter, American College of Physicians
2018	Pursuit of Excellence speaker, Rhode Island Hospital
2019	Appointment by Governor Gina Raimondo to the Advisory Council on Alzheimer's Disease Research and Treatment

**PROFESSIONAL LICENSES & BOARD CERTIFICATIONS:**

1980	Diplomate National Board of Medical Examiners
1981	Rhode Island License Registration, #5819
1985-1989	Massachusetts License Registration, #54356
1982	American Board of Internal Medicine, #85014
1987	American Board of Psychiatry and Neurology, #29864
1994-2004	Geriatric Medicine Added Qualifications, American Board of Internal Medicine, #085014
2004-2014	Geriatric Medicine Added Qualifications, American Board of Internal Medicine, Recertification

**ACADEMIC APPOINTMENTS:**

1982-1985	Clinical Fellow in Neurology, Harvard University Medical School
1989-1996	Assistant Professor, Department of Clinical Neurosciences, Brown University Medical School
1996-2002	Associate Professor, Department of Clinical Neurosciences, Brown University Medical School
2002-2009	Professor, Department of Clinical Neurosciences, Brown University Medical School
2009	Professor, Department of Neurology, Warren Alpert Medical School, Brown University
2011	Adjunct Professor of Pharmacy Practice, University of Rhode Island
2017	Adjunct Professor of Neuroscience, University of Rhode Island

**HOSPITAL APPOINTMENTS:**

1985-1989	Active Staff, Addison Gilbert Hospital, Gloucester, MA
1985-1989	Courtesy Staff, Hunt Memorial Hospital, Danvers, MA
1985-1989	Active Staff, Beverly Hospital, Beverly, MA
1989-1990	Associate Active Staff, Roger Williams Medical Center, Providence, RI
1990-1992	Consultant Staff, U.E. Zambarano Memorial Hospital, Wallum Lake, RI
1990-1996	Active Staff, Roger Williams Medical Center
1997-2005	Courtesy Staff, Roger Williams Medical Center
1996-2005	Active staff, Memorial Hospital of Rhode Island, Pawtucket, RI
1994-2005	Consultant Staff, Rhode Island Hospital, Providence, RI

2005-2009	Consultant Staff, Memorial Hospital of Rhode Island
2009-2018	Courtesy Staff, Memorial Hospital of Rhode Island
2010-2019	Consultant Staff, Women's and Infants Hospital, Providence, RI
2000	Consultant Staff, Miriam Hospital, Providence, RI
2005	Active Staff, Rhode Island Hospital

#### JOURNAL REVIEWER

1985	Kidney International
1996	Journal of Neuropsychiatry and Clinical Neurosciences
1998	Neurology
	Member, Neurology Reviewer Network
2000	Journal of the International Neuropsychological Society
2002	Journal of Gerontology: Medical Sciences
2002	Alzheimer Disease and Associated Disorders
2002	Health and Quality of Life Outcomes
2003	Women's Health in Primary Care
2004	Journal of the American Geriatrics Society
2004	Journal of Geriatric Psychiatry and Neurology
2004	Journal of the American Medical Association
2005	Neuropsychopharmacology
2005	International Journal of Geriatric Psychiatry
2006	Neuropsychology
2006	Canadian Medical Association Journal
2008	Dementia & Geriatric Cognitive Disorders
2011	Aging Health
2011	Journal of Alzheimer's Disease
2011	Accident Analysis & Prevention
2011	Alzheimer's & Dementia
2011	Psychopharmacology
2012	Journal of Neurology, Neurosurgery, and Psychiatry
2013	Neurobiology of Aging
2014	Alzheimer's Research and Therapy
2015	Neurology: Clinical Practice
2016	International Journal of Injury Control and Safety Promotion
2016	Journal of the American Medical Association: Internal Medicine
2016	Annals of Neurology
2016	Journal of General Internal Medicine
2017	Gerontology
2018	American Journal of Alzheimer's Disease and Other Dementias
2018	Psychogeriatrics

#### GRANT REVIEWER

1998	The Wellcome Trust, London, England
2005	Alzheimer's Society, United Kingdom
2006	Netherlands Organization for Scientific Research
2007	Michael Smith Foundation for Health Research, Canada
2007	Medical Research Council, United Kingdom
2007	Alzheimer's Association
2007	Pilot grant program, Indiana Alzheimer Disease Center
2008	Neurological, Aging and Musculoskeletal Epidemiology Study Section, NIH/NIA
2009	Cognition and Perception Study Section, NIH/NIA

2009 Research Foundation – FWO, Flanders, Belgium  
2009 Canada Excellence Research Chairs Program  
2010 Special Emphasis Panel, Aging and Mobility, NIH/NIA  
2011 Small Business Panel: Clinical Neurophysiology, Devices, Auditory Devices and Neuroprosthesis Study Section, NIH/NIA  
2013 Physicians' Services Incorporated Foundation, Canada  
2013 Special Emphasis Panel, Epidemiology and Genetics Study Section, NIH/NEI  
2014 Special Emphasis Panel, Population Sciences and Epidemiology Study Section, NIH/NIA  
2014 Special Emphasis Panel, Child Psychopathology and Developmental Disabilities Study Section, NIH  
2017 Kansas City Area Life Sciences Institute (KCALSII)  
2018 Special Emphasis Panel, Revision Requests for ADCCs and ADRCs, NIH/NIA

OTHER APPOINTMENTS:

1987-1989 Director of Medical Education, Beverly Hospital  
1991 Faculty Associate, Brown University Center for Gerontology and Health Care Research  
1994-1997 Medical Director, Courtyard Assisted Living For Alzheimer's Resident's Unit and advisory board member, The Village At Waterman Lake, Greenville, RI  
1995 Consultant, Health Economics Research  
1996-2005 Associate Chief of Neurology, Memorial Hospital of Rhode Island  
2005 Interim Chief of Neurology, Memorial Hospital of Rhode Island  
1996-1999 Contributor and reviewer for American Board of Internal Medicine Certification Program (Geriatric Medicine examinations)  
1999 Core faculty member, Brown University Center for Primary Care & Prevention  
1999 & 2002 Guest editor, Medicine & Health/Rhode Island  
2000 Steering Committee member, Alzheimer's Disease Cooperative Study  
2005- Internal Ethics subcommittee  
2000 Faculty member, Brown University Brain Science Program  
2002 Journal Editorial Board, Neurological Disease section, for Health and Quality of Life Outcomes  
2003-2008 Core faculty and Steering Committee member, Brown University Dementia Research Program (T-32)  
2004 Steering Committee member, Alzheimer's Disease Neuroimaging Initiative  
1991-1996 Director of the Alzheimer's Disease and Memory Disorders Center, Roger Williams Medical Center  
1996-2005 Director of the Alzheimer's Disease & Memory Disorders Center, Memorial Hospital of Rhode Island  
2005 Director of the Alzheimer's Disease & Memory Disorders Center, Rhode Island Hospital  
2005 Director of the Behavioral Neurology and Memory Disorders Division, Rhode Island Hospital Department of Neurology  
2009-2016 Journal Editorial Board, Neurology Research International  
2011-2012 Associate Editor, The Journal of Alzheimer's Disease  
2011-2015 The Vascular Impairment of Cognition Classification Consensus Study (VICCCS) member  
2013-2014 Board of Directors member, The Neurology Foundation of Rhode Island  
2013-2019 Rhode Island Governor's Advisory Commission on Aging member  
2016- Co-chair, The Isolated Seniors Subcommittee  
2015 Scientific Review Committee, 8th International Driving Symposium on Human Factors in Driver Assessment, June 22-25, Salt Lake City  
2015 Chair, External advisory committee for driving and dementia research. Washington University  
2015 Research partner with the Alzheimer's Therapeutic Research Institute (ATRI)

2015	Semi-Annual Rhode Island Regional Research Meeting planning committee member
2016	Reviewer, Older Driver Management Program, National Highway Traffic Safety Administration
2017	Journal editorial board, Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring
2018	NFL Concussion Settlement Appeals Advisory Panelist
2018-2019	Executive Committee for the Rhode Island State Plan for Alzheimer's Disease Chair, Research Sub-committee
2018-2021	Alzheimer's Clinical Trial Consortium, Internal Ethics Committee member
2019	External Review Committee for the Center for Alzheimer's Disease and Related Disorders, Southern Illinois University School of Medicine
2019-2021	Rhode Island Governor's Advisory Council on Alzheimer's Disease Research and Treatment, member
2021	Block Island Health Services Board of Directors, member

#### HOSPITAL COMMITTEES:

1990-1997	Library, Roger Williams Medical Center
1991-1997	Outpatient Practice, Roger Williams Medical Center
1993-1997	Pharmacy and Therapeutics, Roger Williams Medical Center
1998-2000	Bioethics, Memorial Hospital of Rhode Island
1999-2003	Human Subjects in Research, Memorial Hospital of Rhode Island 2002-2003 Chairman
2006-2007	Ad Hoc Committee for Credentialing the Aging Physician, Rhode Island Hospital
2018-2019	University of Rhode Island/Lifespan Neurosciences Working Group

#### UNIVERSITY COMMITTEES:

1991-1999	Teaching Scholars, Brown University School of Medicine
1991	Fellowships, Brown University School of Medicine, Department of Clinical
1993	Search Committee for director of Neuropsychology, Roger Williams Hospital,
1997	Resident education, Brown University School of Medicine, Department of Clinical Neurosciences
1998	Search Committee for staff neurologist and Brown University full time faculty position
1998	Student clerkship committee leader, Brown University School of Medicine, Department of Clinical Neurosciences
1998-2002	Medical Committee on Academic Standing, Brown University School of Medicine
2001-2003	Search Committee chairperson for staff neurologist and Brown University full time faculty position at Memorial Hospital
2002	Appointments & Promotions Committee, Brown Medical School Department of Neurology
2006	Search Committee for vacancies in Post-Doctoral Training Program in Dementia Research
2007	Committee for Medical Faculty Affairs Task Force, Brown Medical School
2007-2009	Search Committee chairperson for staff neurologist and Brown Medical School full time faculty position at Rhode Island Hospital
2010-2011	Brown Neurology Clerkship working group leader
2015-2017	Search Committee chairperson for staff neurologist and Brown University full time faculty position at Rhode Island Hospital
2018	URI/Lifespan Neurosciences Working Group
2018-2019	Search Committee member for Director of Memory Disorders Program, staff neurologist and Brown Medical School full time faculty position at Rhode Island Hospital

2020                      Affiliated faculty member, Carney Institute for Brain Science

MEMBERSHIP IN SOCIETIES:

1983-1985	Boston Society of Psychiatry & Neurology
1987-1989	Massachusetts Medical Society
1986-1991	Physicians for Social Responsibility
1995-2000	American Neuropsychiatric Association
1996-1998	American Medical Directors Association
1982	American College of Physicians
2008-2016	Executive Council member, Rhode Island Chapter
2012-	Program Planning Committee, Rhode Island Chapter
2014-	National ACP Chapter Leader Network
1983	American Academy of Neurology
1992	Clinical Practice Committee of the Geriatric Neurology Section
1999	Member, Consortium of Neurology Clerkship Directors
2010	Driving Risk in Dementia Dissemination Panel
1989	Rhode Island Neurological Association
1990	Alzheimer's Association, Rhode Island Chapter
	1993-1999      Board of Directors, Alzheimer's Association, Rhode Island Chapter
	1994              Education committee chairperson
	1995-1999      President
1998	American Neurological Association
2010	Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment

PUBLICATIONS:

1. **Ott BR**, Libbey P, Ryter RJ, Trebbin WM. The treatment of schistosome induced glomerulonephritis. Arch Intern Med. 143:1477-1479, 1983.
2. **Ott BR**, Zamani A, Kleefield J, Funkenstein H. The clinical spectrum of hemorrhagic infarction. Stroke. 17:630-37, 1986.
3. **Ott BR**. Bulimia in a patient with temporal lobe epilepsy. J Neurol Neurosurgery & Psychiatry. 54:1020-21, 1991. PMID:1014638
4. Hirano M, **Ott BR**, Raps EC, Minetti C, Lennihan L, Libbey NP, Bonilla E, Hays AP. Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology. 42:2082-2087, 1992.
5. **Ott BR**, Lannon MC. Exacerbation of parkinsonism by tacrine. Clinical Neuropharmacology. 15:222-25, 1992.
6. **Ott BR**, Fogel BS. Measurement of depression in dementia: Self vs clinician rating. Int J Geriatr Psychiatry. 7:899-904, 1992.
7. Farlow M, Gracon SI, Hershey LA, **The Tacrine Study Group**. A controlled trial of tacrine in Alzheimer's disease. JAMA 268:2523- 2529,1992.
8. **Ott BR**, Saver JL. Unilateral amnesic stroke: Six new cases and a review of the literature. Stroke. 24:1033-1042, 1993.

9. Defusco DJ, O'Dowd P, Hokama Y, **Ott BR**. Coma due to ciguatera poisoning in Rhode Island. *Am J Med.* 95:240-243, 1993.
10. **Ott BR**, Elias SA, Lannon MC. Quantitative assessment of movement in Alzheimer's disease. *J Geriatr Psychiatry Neurol.* 8:71-75, 1995.
11. **Ott BR**. Leuprolide treatment of sexual aggression in a patient with dementia and the Kluver-Bucy syndrome. *Clinical Neuropharmacology.* 18:443-447, 1995.
12. Rich SS, Friedman JH, **Ott BR**. Risperidone versus clozapine in the treatment of psychosis in six patients with parkinson's disease and other akinetic-rigid syndromes. *J Clin Psychiatry.* 56:556-559, 1995.
13. **Ott BR**. The clinical importance of gender differences in the presentation and management of Alzheimer's disease. *Nursing Home Med.* 4:1D-6D,1996.
14. **Ott BR**, Noto RB, Fogel BS. Apathy and loss of insight in Alzheimer's disease: A SPECT imaging study. *J Neuropsychiatry Clin Neurosciences.* 8:41-46, 1996.
15. **Ott BR**, Tate CA, Gordon NM, Heindel WC. Gender differences in the behavioral manifestations of Alzheimer's disease. *J Am Geriatr Soc.* 44:583-587, 1996.
16. **Ott BR**, Lafleche G, Whelihan WM, Buongiorno GW, Albert MS, Fogel BS. Impaired awareness of deficits in Alzheimer disease. *Alzheimer Disease Assoc Dis.* 10:68-76, 1996.
17. **Ott BR**, Thompson JA, Whelihan WM. Cognitive effects of flumazenil in patients with Alzheimer's disease. *J Clin Psychopharmacology.* 16:400-402, 1996.
18. **Ott BR**, Faberman RS, Noto RB, Rogg JM, Hough TJ, Tung GA, Spencer PK. A SPECT imaging study of MRI white matter hyperintensity in patients with degenerative dementia. *Dementia Geriatr Cogn Disorders,* 8:348-354,1997.
19. **Ott BR**, Owen NJ. Complementary and alternative medicines for Alzheimer's disease. *J Geriatr Psychiatry Neurol,* 11:163-173, 1999.
20. **Ott BR**. Cognition and behavior in patients with Alzheimer's disease. *J Gender Specific Med,* 2:63-69, 1999.
21. Paul R, Cohen R, **Ott B**, Zawacki T, Moser D, Davis J, Stone W. Cognitive and functional status in two subtypes of vascular dementia. *Neurorehabilitation,* 15(3):199-205, 2000.
22. **Ott BR**, Lapane KL, Gambassi G. Gender differences in the treatment of behavior problems in Alzheimer's disease. *Neurology,* 54:427-432, 2000.
23. Fernandez HH, Lapane KL, **Ott BR**, Friedman JH, for the SAGE Study Group. Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. *Movement Disorders,* 15:490-496, 2000.
24. **Ott BR**, Heindel WC, Whelihan WM, Caron MD, Piatt AL, Noto RB. A SPECT imaging study of driving impairment in patients with Alzheimer's disease. *Dementia Geriatric Cogn Disorders,* 11:153-160, 2000. PMID:3292192
25. **Ott BR**, Heindel WC, Tan Z, Noto RB. Lateralized cortical perfusion in women with Alzheimer's disease. *J Gender Specific Med,* 3:29-35, 2000.

26. **Ott BR**, Noto RB. Sensitivity of SPECT for the diagnosis of Alzheimer's disease. *Clin Gerontologist*, 22(1):73-82, 2000.
27. Paul R, Cohen R, Moser D, **Ott BR**, Gordon N, Zawacki T, Bell S, Stone W. Performance on the Mattis Dementia Rating Scale among patients with vascular dementia: relationships to neuroimaging findings. *J Geriatr Psychiatry Neurol*, 14(1):33-6, 2001
28. Moser DJ, Cohen RA, Paul R, Paulsen JS, **Ott BR**, Gordon N, Bell S, Stone W. Executive function and magnetic resonance imaging subcortical hyperintensities in vascular dementia. *Neuropsych Neuropsychol Behav Neurol*, 14(2):89-92, 2001
29. Paul R, Cohen R, Moser D, **Ott BR**, Zawacki T, Gordon N. Performance on the Hooper Visual Organizational Test in patients diagnosed with subcortical vascular dementia: Relation to naming performance. *Neuropsych Neuropsychol Behav Neurol*, 14(1):93-97, 2001.
30. Cohen RA, Paul RH, Zawacki TM, Sethi M, **Ott BR**, Moser DJ, Stone W, Noto R, Gordon N. Single photon emission computed tomography, magnetic resonance imaging hyperintensity, and cognitive impairments in patients with vascular dementia. *J Neuroimaging*, 11(3):253-260, 2001.
31. **Ott BR**, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. *J Am Geriatric Soc*, 50:35-40, 2002.
32. Cahn-Weiner DA, Grace J, **Ott BR**, Fernandez HH, Friedman JH. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's patients. *Neuropsych Neuropsychol Behav Neurol*, 15(2):79-87, 2002.
33. Paul RH, Cohen RA, Moser DJ, Zawacki T, **Ott BR**, Gordon N, Stone W. The Global Deterioration Scale: relationships to neuropsychological performance and activities of daily living in patients with vascular dementia. *J Geriatr Psychiatry Neurol*, 15(1):50-54, 2002.
34. Ready RE, **Ott BR**, Grace J, Fernandez I. The Cornell-Brown Scale for quality of life in dementia. *Alzheimer Dis Assoc Disord*, 16(2):109-115, 2002.
35. Cohen RA, Paul R, Moser D, Stone W, **Ott BR**, Zawacki T, Gordon N. The relationship of MRI hyperintensities and brain volume to cognitive function in vascular dementia. *J Int Neuropsychol Soc*, 8(6):743-752, 2002.
36. **Ott BR**, Belazi D, Lapane KL. Cognitive decline among female estrogen users in nursing homes. *J Gerontol A Biol Sci Med*, 57(9):M594-M598, 2002.
37. Zawacki TM, Grace J, Paul RH, Moser DJ, **Ott BR**, Gordon N, Cohen RA. Behavioral problems as predictors of functional abilities of vascular dementia patients. *J Neuropsychiatry Clin Neurosci*, 14(3):296-302, 2002.
38. Ready RE, **Ott BR**, Grace J. Amnesic behavior in dementia: symptoms to assist in early detection and diagnosis. *J Am Geriatric Soc* 51:32-37, 2003.
39. Ready RE, Grace J, **Ott BR**, Cahn-Weiner D. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer's disease. *Am J Geriatr Psychiatry*, 11(2):222-228, 2003.
40. Paul RH, Cohen RA, Moser DJ, **Ott BR**, Sweet L, Browndyke J, Malloy P, Garrett K. Clinical correlates of cognitive decline in vascular dementia. *Cogn Behav Neurol*, 16(1):40-46, 2003.
41. **Ott BR**, Heindel WC, Papandonatos GD. A survey of voter participation by cognitively impaired elderly patients. *Neurology*, 60:1546-1548, 2003.

42. Ready RE, **Ott BR**. Quality of life measures for dementia. *Health Qual Life Outcomes*, Apr 23;1(1):11, 2003. PMID:155631
43. Sweet LH, Paul RH, Cohen RA, Moser D, **Ott BR**, Gordon N, Browndyke J, Shah P, Garrett KD. Neuroimaging correlates of Dementia Rating Scale performance at baseline and 12-month follow-up among patients with vascular dementia. *J Geriatr Psych Neurol* 16(4):240-244, 2003.
44. Cahn-Weiner DA, Malloy PF, Rebok GW, **Ott BR**. Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients. *Appl Neuropsychol* 10(4):215-223, 2003.
45. **Ott BR**, Heindel WC, Whelihan WM, Caron MD, Piatt AL, DiCarlo MA. Maze test performance and reported driving ability in early dementia. *J Geriatr Psych Neurol*. 16(3):151-155, 2003. PMID:3292212
46. Ready RE, **Ott BR**, Grace J. Patient vs informant perspectives of quality of life in mild cognitive impairment and Alzheimer's disease. *Int J Geriatr Psychiatry* 19(3):256-265, 2004.
47. Ready RE, **Ott BR**, Grace J. Validity of informant reports about AD and MCI patients' memory. *Alz Disease Assoc Disorders* 18(1):11-16, 2004.
48. Festa-Martino E, **Ott BR**, Heindel WC. Interactions between phasic alerting and exogenous attentional orienting: Effects of normal aging and Alzheimer's disease. *Neuropsychology* 18(2):258-268, 2004.
49. Garrett KD, Browndyke JN, Whelihan W, Paul RH, DiCarlo M, Moser DJ, Cohen RA, **Ott BR**. The neuropsychological profile of vascular cognitive impairment - no dementia: Comparisons to patients at risk for cerebrovascular disease and vascular dementia. *Arch Clin Neuropsychology*, 19(6):745-757, 2004.
50. Brown LB, **Ott BR**. Driving and dementia: A review of the literature. *J Geriatr Psychiatry Neurol* 17(4):232-240, 2004. PMID:3292210
51. Stern RA, Davis JD, Rogers BL, Smith KM, Harrington CJ, **Ott BR**, Jackson IM, Prange AJ. Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer's dementia. *Cognitive and Behavioral Neurology*. 17(4):219-223, 2004.
52. Brown LB, **Ott BR**, Papandonatos GD, Sui Y, Ready RE, Morris JC. Prediction of on-road driving performance by patients with mild Alzheimer's disease. *J Am Geriatr Soc*. 53(1):94-98, 2005. PMID:3292197
53. Gunstad J, Brickman AM, Paul RH, Browndyke J, Moser DJ, **Ott BR**, Gordon N, Cohen RA. Progressive morphometric and cognitive changes in vascular dementia. *Arch Clin Neuropsychology*. 20:229-241, 2005.
54. Brown LB, Stern RA, Cahn-Weiner DA, Rogers B, Meser MA, Lannon MC, Maxwell C, Souza T, White T, **Ott BR**. Driving scenes test of the Neuropsychological Assessment Battery (NAB) and on-road driving performance in aging and very mild dementia. *Arch Neuropsychology*. 20:209-215, 2005. PMID:3292213
55. Gasper MC, **Ott BR**, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? *Am J Geriatric Pharmacotherapy* 3(1):1-7, 2005.
56. **Ott BR**, Anthony D, Papandonatos GD, Sui Y, D'Abreu A, Burock J, Curtin A, Wu C-K, Morris JC. Clinician assessment of the driving competence of patients with dementia. *J Am Geriatric Soc* 53(5):829-833, 2005. PMID:3292185

57. Grace J, Amick MM, D'Abreu A, Festa-Martino EK, Heindel WC, **Ott BR**. Neuropsychological deficits associated with driving performance in Parkinson's and Alzheimer's disease. *J Int Neuropsychol Soc* 11(6): 766-775, 2005. PMID:3292203
58. Peskind E, Potkin S, Pomara N, **Ott BR**, McDonald S, Xie Y, Gergel I. Memantine treatment in mild to moderate Alzheimer's disease: A randomized controlled trial. *Am J Geriatr Psychiatry* 14:704-715, 2006.
59. Ready RE, **Ott BR**, Grace J. Insight and cognitive impairment: effects on quality of life reports from mild cognitive impairment and Alzheimer's disease patients. *Am J Alzheimers Dis Other Demen* 21(4):242-248, 2006.
60. Amick MM, D'Abreu A, Moro-de-Casillas ML, Chou KL, **Ott BR**. Excessive daytime sleepiness and on-road driving performance in individuals with Parkinson's disease. *J Neurological Sci* 252(1):13-15, 2006.
61. Ready RE, **Ott BR**, Grace J. Factor structure of patient and informant ratings on the Dementia Quality of Life Instrument. *Aging Neuropsychology Cognition* 14(2):144-154, 2007.
62. **Ott BR**, Blake LM, Sauter M, Graham SM, Bell JM. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. *J Neurol* 254(3):351-358, 2007.
63. Bhalla RK, Papandonatos GD, Stern RA, **Ott BR**. Anxiety of Alzheimer's disease patients before and after a standardized on-road driving test. *Alzheimer's & Dementia* 3(1):33-39, 2007. PMID:3598633
64. Pomara N, **Ott BR**, Peskind E, Resnick EM. Treatment of cognitive symptoms with memantine in mild to moderate Alzheimer's disease: Secondary analyses from a placebo-controlled randomized trial. *Alzheimer Dis Assoc Disord* 21(1):60-64, 2007.
65. Ready RE, **Ott BR**. Integrating patient and caregiver reports on the Cornell-Brown Quality of Life scale. *Am J Alzheimer's Dis Other Demen* 22(6):528-34, 2007.
66. Amick MM, Grace J, **Ott BR**. Visual and cognitive predictors of driving safety in Parkinson's disease patients. *Arch Clin Neuropsychol* 22(8):957-67, 2007. PMID:3555123
67. **Ott BR**, Heindel WC, Papandonatos GD, Festa EK, Davis JD, Daiello LA, Morris JC. A longitudinal study of drivers with Alzheimer disease. *Neurology* 70(14):1171-1178, 2008. PMID:3664938
68. **Ott BR**, Festa EK, Amick M, Grace J, Davis J, Heindel WC. Computerized maze navigation and on-road performance by drivers with dementia. *J Geriatr Psychiatry Neurol* 21(1):18-25, 2008. PMID:3292182
69. Smith MM, Tremont G, **Ott BR**. Telephone administered dementia screening. *Am J Alz Disease Other Dementias* 24(1):58-69, 2009.
70. Daiello LA, **Ott BR**, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. *Am J Geriatr Pharmacother* 7(2):74-83, 2009.
71. **Ott BR**, Daiello LA. How does dementia affect driving in older patients? *Aging Health*, 6(1):77-85, 2010. PMID: PMC2847266
72. **Ott BR**, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. *J Alzheimers Dis* 20(2):647-657, 2010. PMID:3078034

73. Carr D, **Ott BR**. The older driver with cognitive impairment: "It's a very frustrating life." *JAMA* 303(6):1632-1641, 2010. PMID:2915446
74. Daiello LA, **Ott BR**, Festa EK, Friedman M, Miller LA, Heindel WC. Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease. *J Clin Psychopharmacol.* 30(3):245-51, 2010. PMID:3289132
75. Festa, EK, Heindel WC, **Ott BR**. Dual-task conditions modulate the efficiency of selective attention mechanisms in Alzheimer's disease. *Neuropsychologia* 48:3252-3261, 2010. PMID:2928570
76. Okonkwo OC, Alosco ML, Jerskey BA, Sweet LH, **Ott BR**, Tremont G. Cerebral atrophy, apolipoprotein E  $\epsilon$ 4, and rate of decline in everyday function among patients with amnesic mild cognitive impairment. *Alzheimers Dement. Sep*;6(5):404-11, 2010. PMID:2950092
77. Silverberg N, Ryan L, Carrillo M, Sperling R, Petersen R, Posner HB, Snyder PJ, Hilsabeck R, Gallagher M, Raber J, Rizzo A, Possin K, King J, Kaye J, **Ott BR**, et al. Assessment of cognition in early dementia. *Alzheimers Dementia.* 7(3):e60-76, 2011. PMID:3613863
78. Carr DB, Barco PP, Wallendorf MJ, Snellgrove CA, **Ott BR**. Predicting road test performance in drivers with dementia. *J Am Geriatr Soc*, 59:2112-2117, 2011. PMID: 3228409
79. Tremont G, Papandonatos GD, Springate B, , Huminski B, McQuiggan MD, Grace J, Frakey L, **Ott BR**. Use of the telephone-administered Minnesota Cognitive Acuity Screen to detect mild cognitive impairment. *Am J Alzheimers Dis Other Demen*, 26(7): 555 – 562, 2011. PMID 22127023
80. Alosco, ML, **Ott BR**, Cleveland MJ, Royle K, Snyder S, Spitznagel MB, Gunstad, J. Impaired knowledge of driving laws is associated with recommended driving cessation in cognitively impaired older adults. *Dement Geriatr Cogn Dis Extra*, 1(1):358-365, 2012. PMID:3243640
81. **Ott BR**, Papandonatos GD, Davis JD, Barco PP. Naturalistic validation of an on-road driving test of older drivers. *Human Factors*, 54(4):663 – 674, 2012. PMID:3568996
82. Davis J, Papandonatos GD, Miller LA, Hewitt SD, Festa EK, Heindel WC, **Ott BR**. Road test and naturalistic driving performance in healthy and cognitively impaired older adults: Does environment matter? *J Am Geriatr Soc*, 60(11):2056-2062, 2012. PMID:3498523
83. Springate BA, Tremont G, **Ott BR**. Predicting functional impairments in cognitively impaired older adults using the Minnesota Cognitive Acuity Screen. *J Geriatr Psychiatry Neurol*, 25(4):195-200, 2012. PMID 23172763
84. Lucas-Carrasco R, Gomez-Benito J, Rejas J, **Ott BR**. The Cornell-Brown Scale for Quality of Life in Dementia: Adaptation and validation into Spanish. *Alzheimer Dis Assoc Disord*, 27(1):44-50, 2013. PMID 22193352
85. Festa EK, **Ott BR**, Manning KJ, Davis JD, Heindel WC. Effect of cognitive status on self-regulatory driving behavior in older adults: An assessment of naturalistic driving using in-car video recordings. *J Geriatr Psychiatr Neurol*, 26(1):10-18, 2013. PMID 23385363
86. Heindel WC, Festa EK, **Ott BR**, Landy K, Salmon DP. Prototype learning and dissociable categorization systems in Alzheimer's disease. *Neuropsychologia*, 51:1699-1708, 2013. PMID:23751172
87. Zahodne LB, Gongvatana A, Cohen RA, **Ott BR**, Tremont G. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? *Am J Geriatr Psychiatry*,

21(11):1098-106, 2013. PMID:3797189

88. **Ott BR**, Davis JD, Papandonatos GD, Hewitt S, Festa EK, Heindel WC, Snellgrove CA, Carr DB. Assessment of Driving-Related Skills prediction of unsafe driving in older adults in the office setting. *J Am Geriatr Soc*, 61(7):1164-9, 2013. PMID:23730836

89. Tremont G, Davis J, Papandonatos GD, Grover C, **Ott BR**, Fortinsky RH, Gozalo P, Bishop BS. A telephone intervention for dementia caregivers: Background, design, and baseline characteristics. *Contemp Clin Trials*, 36(2):338-347, 2013. PMID:3844092

90. Barco PP, Wallendorf MJ, Snellgrove CA, **Ott BR**, Carr DB. Predicting road test performance in drivers with stroke. *Am J Occup Ther* 68(2):221-0, 2014. PMID:4012570

91. Manning KJ, Davis JD, Papandonatos GD, Hewitt SD, **Ott BR**. Clock drawing as a screen for impaired driving in aging and dementia: Is it worth the time? *Arch Clin Neuropsychol* 29(1):1-6, 2014. PMID:3897234

92. Springate BA, Tremont G, Papandonatos G, **Ott BR**. Screening for mild cognitive impairment using the Dementia Rating Scale-2. *J Geriatr Psychiatry Neurol* 27(2):139-144, 2014. PMID:24578462

93. Snyder PJ, Lim YY, Schindler R, **Ott BR**, Salloway S, Daiello L, Getter C, Gordon CM, Maruff P. Micro-dosing of scopolamine as a “cognitive stress test”: Rationale and test of a very low dose in an at-risk cohort of older adults. *Alzheimers Dement*, 10(2):262-7, 2014. PMID 24698030

94. Buelow MT, Tremont G, Frakey LL, Grace J, **Ott BR**. Utility of the cognitive difficulties scale and association with objective test performance. *Am J Alzheimers Dis Other Dement*. 29(8):755-61, 2014. PMID 24928819

95. Daniels AH, Daiello LA, Lareau CR, Robidoux KA, Luo W, **Ott B**, Hayda RA, Born CT. Preoperative cognitive impairment and psychological stress in hospitalized elderly hip fracture patients. *Am J Orthop*. 43(7):E146-52, 2014. PMID:25046191

96. Daiello LA, Gongvatana W, Dunsiger S, Cohen R, **Ott BR**. Association of fish oil use with preservation of brain volume and cognitive function. *Alzheimers Dement*. 11(2):226-35, 2015. PMID:4829435

97. Tremont G, Davis JD, Papandonatos GD, **Ott BR**, Fortinsky RH, Gozalo P, Yue MS, Bryant K, Grover C, Bishop DS. Psychosocial Telephone Intervention for Dementia Caregivers: A Randomized, Controlled Trial. *Alzheimers Dement*. 11(5):541-8, 2015. PMID:4306648

98. Alosco ML, Penn MS, Spitznagel MB, Cleveland MJ, **Ott BR**, Gunstad J. Reduced physical fitness patients with heart failure as a possible risk factor for impaired driving performance. *Am J Occup Ther*, 69(2):1-8, 2015. PMID:4480054

99. Bixby KA, Davis JD, **Ott BR**. Comparing caregiver and clinician prediction of fitness-to-drive in people with Alzheimer’s disease. *Am J Occup Ther*, 69(3):1-7, 2015. PMID:4453038

100. **Ott BR**, Daiello LA, Dahabreh II, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statin drugs impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Int Med*. 30(3):348-58, 2015. PMID:4351273

Cited for discussion in *Ann Int Med*, ACP Journal Club, May 19, 2015.

101. Barco PP, Baum CM, **Ott BR**, Ice S, Johnson A, Wallendorf M, Carr DB. Driving errors in persons with dementia. *J Am Geriatr Soc*. 63(7):1373-80, 2015. PMID: 26140521

102. Lim YY, Maruff P, Schindler R, **Ott BR**, Salloway S, Yoo D, Noto RB, Snyder PJ. Disruption of cholinergic neurotransmission exacerbates A $\beta$ -related cognitive impairment in preclinical Alzheimer's disease. *Neurobiol Aging*. 36(10):2709-15, 2015. PMID:26233262
103. Papandonatos GD, **Ott BR**, Davis JD, Barco P, Carr DB. The clinical utility of the trail making tests as predictors of driving performance in older adults. *J Am Geriatr Soc*. 63(11):2358-64, 2015. PMID:4661063
104. Tremont G, Papandonatos GD, Kelley P, Bryant K, Galioto R, **Ott BR**. Prediction of cognitive and functional decline with the telephone-administered Minnesota Cognitive Acuity Screen. *J Am Geriatr Soc*. 64(3):608-13, 2016. PMID:27000332
105. Alosco ML, Penn MS, Spitznagel MB, Cleveland MJ, **Ott BR**, Gunstad J. Preliminary investigation on the association between depressive symptoms and driving performance in heart failure. *Geriatrics* 2016, 1(1), e2; <http://www.mdpi.com/2308-3417/1/1/2>
106. **Ott BR**, Pelosi M, Tremont G, Snyder PJ. A survey of knowledge and views concerning genetic and amyloid PET status disclosure. *Alzheimers Dement (N Y)*. 2(1):23-29, 2016. PMID:4804344  
Comment in *AlzForum*, September 12, 2016
107. **Ott BR**, Davis JD, Bixby K. Video feedback intervention to enhance the safety of cognitively impaired older drivers. *Am J Occup Ther*. 71(2):1-7, 2017. PMID:5317390
108. Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, **Ott BR**, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC. Amyloid imaging, cerebrospinal fluid biomarkers, and driving performance among cognitively normal individuals. *Alzheimer Dis Assoc Disord*. 31(1):69-72, 2017. PMID:5085874
109. Tremont G, Davis JD, **Ott BR**, Galioto R, Crook C, Papandonatos G, Fortinsky RH, Gozalo P, Bishop DS. Randomized trial of the family intervention: Telephone Tracking-Caregiver for Dementia Caregivers: Use of community and healthcare resources. *J Am Geriatr Soc*. 65(5):924-930, 2017. PMID:28008609.
110. Babulal GM, Traub CM, Webb M, Stout SH, Addison A, Carr DB, **Ott BR**, Morris JC, Roe CM. Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. *F1000Res*. 5:2376. eCollection 2016. PMID:5133689
111. **Ott BR**, Jones RN, Noto RB, Yoo DC, Snyder PJ, Bernier JN, Carr DB, Roe CM. Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk. *Alzheimers Dement (Amst)*. 6:136-142, 2016. eCollection 2017. PMID:5318288
112. Skrobot OA, O'Brien J, Black S, and **The VICCCS group**. The Vascular Impairment of Cognition Classification Consensus Study (VICCCS). *Alzheimers Dement*. 13:624-33, 2017. PMID:27960092.
113. Babulal GM, Stout SH, Benzinger TL, **Ott BR**, Carr DB, Webb M, Traub CM, Addison A, Morris JC, Warren DK, Roe CM. A naturalistic study of driving behavior in older adults and preclinical Alzheimer disease. *J Appl Gerontol*. Jan 1:733464817690679, 2017 [Epub ahead of print] PMID:28380718
114. Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, **Ott BR**, Carr DB, Morris JC. Preclinical Alzheimer disease and longitudinal driving decline. *Alzheimers Dement (N Y)*. 3(1):74-82, 2017. PMID:5396459

115. Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman S, **Ott BR**, on behalf of the EBBINGHAUS Investigators. Design and Rationale of the EBBINGHAUS Trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid lowering therapy – A cognitive study of patients enrolled in the FOURIER trial. *Clin Cardiol.* 40(2):59-65, 2017. PMID:28207168
116. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman, SM, **Ott BR**, on behalf of the EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. *New Eng J Med.* 377(7):633-643, 2017. PMID:28813214
117. Festa EK, Katz AP, **Ott BR**, Tremont G, Heindel WC. Dissociable effects of aging and mild cognitive impairment on bottom-up audiovisual integration. *J Alzheimers Dis.* 59(1):155-167, 2017. PMID:28598838
118. Giugliano RP, Pedersen TR, Park J-G, De Ferrari G, Gaciog Z, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, **Ott BR**, Kanevsky E, Pineda AL, Somaratne R, Keech AC, Sever PS, Sabatine MS, on behalf of the FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. *Lancet* 390(10106):1962-1971, 2017. PMID:28859947
119. Margolis SA, Papandonatos GD, Tremont G, **Ott BR**. Telephone-administered Minnesota Cognitive Acuity Screen predicts time to institutionalization and homecare. *Int Psychogeriatr.* 30(3):365-373, 2018. PMID:28942736
120. Roe CM, Babulal GM, Mishra S, Gordon BA, Stout SH, **Ott BR**, Carr DB, Ances BM, Morris JC, Benzinger TLS. Tau and amyloid positron emission tomography imaging predict driving performance among older adults with and without preclinical Alzheimer Disease. *J Alzheimers Dis.* 61(2):509-513, 2018. PMID:29171997  
PMCID:5784441
121. De la Monte SM, Daiello LA, Hapel AJ, Tong M, **Ott BR**. Altered serum and cerebrospinal fluid inflammatory cascades in mild cognitive impairment and Alzheimer’s disease. *Neuroinflamm Neurodegen* (1):September 29, e1, 2017. <https://www.onjourn.com/open-access/altered-serum-and-cerebrospinal-fluid-inflammatory-cascades-in-mild-cognitive-impairment-and-alzheimers-disease-100004.pdf>
122. Skrobot OA, Black S, Chen C, et al. and **The VICCCS group**. Progress towards standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study (VICCCS). *Alzheimers Dement*, 14(3):280-292, 2018. PMID:29055812
123. Venkatesan U, Festa EK, **Ott BR**, Heindel WC. Differential contributions of selective attention and sensory integration to driving performance in healthy aging and Alzheimer’s disease. *J Int Neuropsychol Soc.* 24(5):486-497, 2018. PMID:29283079 PMCID:5910249
124. Wang S, **Ott BR**, Luo G. Detection of lane-change events in naturalistic driving videos. *Intern J Pattern Recognit Artif Intell.* 32(10): e1850030, 2018. <https://doi.org/10.1142/S0218001418500301> PMID: 29962563  
PMCID: PMC6020696 DOI: 10.1142/S0218001418500301
125. Davis JD, Wang S, Luo G, Moharrer M, Festa EK, Bernier J, **Ott BR**. Detection of risky driving behaviors in the naturalistic environment in healthy older adults and mild Alzheimer's disease. *Geriatrics*, 3:e13, 2018. <http://www.mdpi.com/2308-3417/3/2/13/pdf>; PMID:29632868 PMCID:5889300

126. Pillemer S, Papandonatos GD, Crook C, **Ott BR**, Tremont G. The Modified Telephone-Administered Minnesota Cognitive Acuity Screen for mild cognitive impairment. *J Geriatr Psychiatry Neurol.* 31(3):123-128, 2018. PMID:29764279
127. Johanson C, Daiello LA, Stopa E, de la Monte S, Keane M, **Ott BR**. Disrupted blood-CSF barrier to urea and creatinine in mild cognitive impairment and Alzheimer's disease. *J Alzheimers Dis Parkinsonism* April 7; 8(2): e435, 2018. <https://www.omicsonline.org/open-access/disrupted-bloodcsf-barrier-to-urea-and-creatinine-in-mild-cognitive-impairment-and-alzheimers-disease-2161-0460-1000435-100941.html>
128. **Ott BR**, Jones RN, Daiello LA, de la Monte SM, Stopa EG, Johanson CE, Denby C, Grammas P. Blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer's disease: Relationship to inflammatory cytokines and chemokines. *Front Aging Neurosci.* Aug 21;10:e245, 2018. <https://www.frontiersin.org/articles/10.3389/fnagi.2018.00245/full> PMID:30186149
129. **ASPREE Investigator Group**. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. *Contemp Clin Trials.* 2013 Nov;36(2):555-64. PMID:24113028; PMCID:PMC3919683
130. De la Monte SM, Tong M, Daiello LA, **Ott BR**. Early-stage Alzheimer's disease is associated with simultaneous systemic and central nervous system dysregulation of insulin-linked metabolic pathways. *J Alzheimers Dis.* 68(2):657-668, 2019. PMID:30775986
131. Roe CM, Stout SH, Rajasekar G, Ances BM, Jones JM, Head D, Benzinger TLS, Williams MM, Davis JD, **Ott BR**, Warren DK, Babulal GM. A 2.5-year longitudinal assessment of naturalistic driving in preclinical Alzheimer's disease. *J Alzheimers Dis.* 68(4):1625-1633, 2019. PMID:30958365; PMCID:6488385
132. Margolis SA, Festa EK, Papandonatos GD, Korthauer LE, Gonsalves MA, Oberman L, Heindel WC, **Ott BR**. A pilot study of repetitive transcranial magnetic stimulation in primary progressive aphasia. *Brain Stimul.* 12(5): 1340-1342, 2019. PMID:31186160
133. Karpouzian-Rogers T, Heindel WC, **Ott BR**, Tremont G, Festa EK. Phasic alerting enhances spatial orienting in healthy aging but not in mild cognitive impairment. *Neuropsychology* 34(2):144-154, 2020. PMID:31464472.
134. Moharrer M, Wang S, Davis JD, **Ott BR**, Luo G. Driving safety of cognitively-impaired drivers based on near collisions in naturalistic driving. *J Alzheimers Dis Rep.* Jan 2;4(1):1-7, 2020. PMID: 32104782 PMCID: PMC7029310 DOI: 10.3233/ADR-190159
135. Alber J, Maruff P, Santos CY, **Ott BR**, Salloway SP, Yoo DC, Noto RB, Thompson LI, Goldfarb D, Song A, Snyder PJ. Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is predictive of A $\beta$ -related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay interval. *Alzheimers Res Ther* 12(1):e31, 2020. <https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00599-1> PMID: 32209123 PMCID: PMC7093953
136. Gencer B, , Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pederson TR, Keech AC, **Ott BR**, Sabatine MS, Giugliano RP, on Behalf of the FOURIER Investigators. Impact of lowering LDL-C with evolocumab on patient reported cognition from the FOURIER trial. *J Am College Cardiology* 75(18):2283-2293, 2020. PMID:32381158
137. Korthauer LE, Heindel WC, Lai LY, Tremont G, **Ott BR**, Festa EK. Impaired integration of object feature knowledge in amnesic mild cognitive impairment. *Neuropsychology*, 34(6):699-712, 2020. PMID:32551739 DOI: 10.1037/neu0000670

138. Moharrer M, Wang S, Dougherty BE, Cybis W, **Ott BR**, Davis J, Luo G. Evaluating driving safety of visually impaired bioptic drivers based on critical events in naturalistic driving. *Trans Vis Sci Tech*, Jul 9;9(8):e14, 2020. <https://tvst.arvojournals.org/article.aspx?articleid=2770285> PMID: 32855861 PMCID: PMC7422772 DOI: 10.1167/tvst.9.8.14

139. Margolis SA, Kelly DA, Daiello LA, Davis J, Tremont G, Pillemer S, Denby C, **Ott BR**. Anticholinergic/sedative drug burden and subjective cognitive decline in older adults at risk of Alzheimer's disease. *J Gerontol A Sci Med Sci*. Sept 4, 2020. PMID: 32886748 DOI: 10.1093/gerona/glaa222

140. Davis JD, Babulal GM, Papandonatos GD, Burke EM, Rosnick CB, **Ott BR**, Roe CM. Evaluation of naturalistic driving behavior using in-vehicle monitoring technology in preclinical and early Alzheimer's disease. *Front Psychol* 11:e596257. Oct27, 2020. <https://www.frontiersin.org/articles/10.3389/fpsyg.2020.596257/full> PMID: 33192943 PMCID: PMC7653196 DOI: 10.3389/fpsyg.2020.596257

141. **Ott BR**, Papandonatos GD, Burke EM, Erdman D, Carr DB, Davis JD. A video feedback intervention for cognitively impaired older drivers. *Translational Research & Clinical Interventions. Alzheimer's Dement*. 7:e12140, 2021. <https://doi.org/10.1002/trc2.12140> 2020. PMID: 33718583 PMCID: PMC7927162 DOI: 10.1002/trc2.12140

142. Korthauer LE, Denby C, Molina D, Wanjiku J, Daiello LA, Drake J, Grill JD, **Ott BR**. Pilot study of an Alzheimer's disease risk assessment program in a primary care setting. *Diagnosis, Assessment & Disease Monitoring. Alzheimer's Dement*. 13:e12157, 2021. <https://doi.org/10.1002/dad2.12157>. PMID: 33665347 PMCID: PMC7896638 DOI: 10.1002/dad2.12157

143. Drake JD, Chambers AB, **Ott BR**, Daiello LA. Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in Alzheimer's disease. *J Alzheimers Dis*. 80(4):1553-1565, 2021. PMID: 33720880 DOI: 10.3233/JAD-200759.

144. Alber J, Arthur E, Goldfarb D, Drake J, Boxerman J, Silver B, **Ott BR**, Johnson LN, Snyder PJ. The relationship between cerebral and retinal microbleeds in Cerebral Amyloid Angiopathy (CAA): A pilot study. *J Neurol Sci*. 423:e117383, April 15, 2021. <https://www.jns-journal.com/article/S0022-510X%2821%2900076-9/fulltext> PMID: 33684655 DOI: 10.1016/j.jns.2021.117383

#### OTHER PUBLICATIONS:

1. **Ott BR**, Tornabene J, Fogel BS. Deficit awareness in dementia: Relevance to the clinical diagnosis of Alzheimer's disease. In: Nicolini N, Corain B, Zatta PF, eds. *Alzheimer's Disease and Related Disorders*. Advances in the Biosciences. Vol. 87. New York: Pergamon Press, pp. 63-65, 1993.
2. **Ott BR**. An adult with spina bifida and recurrent urinary tract infections. *Neurology Reviews*, 1:29, 1993.
3. **Ott BR**. Diagnosis and treatment of depression in patients with dementia. *The Brown University Long-Term Care Quality Letter*. 5(18):1,6-7,1993.
4. **Ott BR**. Huntington's disease. *Rhode Island Medical Journal*. 76:543-545, 1993.
5. **Ott BR**. Alzheimer's disease. In: Feldmann E, ed. *Current Diagnosis in Neurology*. Mosby-Year Book, Inc. 1994, pp. 173-177.
6. DeFusco DJ, **Ott BR**, O'Dowd P, Hokama Y. Coma due to ciguatera poisoning in Rhode Island (letter). *Am J Med* 99:106-107,1995.

7. **Ott BR.** Case study: A 57-Year-old man with numbness of the chin. *Neurology Reviews*, 3:14, 1995.
8. **Ott BR.** Non-Alzheimer dementing disorders. In: Sage JI, Mark MH, eds. *Practical Neurology of the Elderly*. New York, Marcel Dekker, Inc. 1996, pp. 49-114.
9. **Ott BR.** Driving and dementia: The medical perspective. *Med Health/RI*. 79:383-387,1996.
10. **Ott BR,** Grace J. Vascular dementia. *Med Health/RI*. 80:150-154,1997.
11. Noto RB, **Ott BR.** Brain SPECT scanning (letter). *J Am Geriatr Soc* 46:657-658,1998.
12. **Ott BR.** Alzheimer's disease and other cortical dementias. In: Gilchrist JM, ed. *Prognosis In Neurology*. Boston, Butterworths. 1998, pp.125-129.
13. Abuelo DN, Walsh A, Seltzer W, Anath U, **Ott BR,** Geffroy G. Premature Alzheimer disease was not due to trauma: molecular biology revises diagnosis 15 years after patient's autopsy (letter). *Arch Neurol* 55:1155, 1998.
14. **Ott BR.** Book review: Headache, by ELH Spierings, in *Med Health/RI* 81:279, 1998.
15. Friedman JH, **Ott BR.** Should risperidone be used in patients with Parkinson's disease? (letter). *J Neuropsychiatry Clin Neurosciences* 10:473-475, 1998.
16. **Ott BR,** Mernoff ST. Driving policy issues and the physician. *Med Health/RI* 82:428-431, 1999.
17. **Ott BR.** Book review: *Concepts of Alzheimer's Disease -- Biological, Clinical, and Cultural Perspectives*, ed, by PJ Whitehouse, K. Maurer, and JF Ballenger. *Clinical Gerontologist* 22:141-142, 2001.
18. **Ott BR,** Cahn-Weiner D. Gender differences in Alzheimer's disease. *Geriatric Times* 2(6):23-24, 2001.
19. White T, Stern RA. *Neuropsychological Assessment Battery*. Reliability and validity studies, **Brian Ott,** contributor. Psychological Assessment Resources, Inc. Lutz, FL. 2001, 2003.
20. **Ott BR.** Medical treatment of Alzheimer's disease: Past, present, and future. *Med Health/RI*, 85(7):210-212, 2002.
21. Ready RE, **Ott BR,** Grace J. Assessment of quality of life in Alzheimer's disease and mild cognitive impairment. In: *Research and Practice in Alzheimer's Disease and Cognitive Decline*. Vol. 7. B Vellas, M Grundman, H Feldman, LJ Fitten, B Winblad, E Giacobini, eds., Serdi, 2003.
22. **Ott BR.** Gender differences in the behavior of Alzheimer Disease patients. In: *Alzheimer's Disease – The Basics. A Physician's Guide to the Practical Management*. RW Richter, BZ Richter, Eds., Humana Press, Inc., Totowa, NJ, 2003, pp353-361.
23. **Ott BR,** Cahn-Weiner D. Gender differences in Alzheimer's disease. *Psychiatric Times* 20(2):46-51, 2003.
24. Fernandez HH, Wu CK, **Ott BR.** Pharmacotherapy of Dementia with Lewy Bodies. *Expert Opin Pharmacother*, 4(11):2027-2037, 2003.
25. Heindel W, Festa-Martino A, **Ott B.** Retrieval from semantic memory: Differential effects of aging and Alzheimer's disease. MIT CogNet, 2003.

26. Naor-Raz G, Heindel W, Tarr M, **Ott B**. Object recognition impairments in Alzheimer's disease. MIT CogNet, 2003.
27. Paul R, Cohen RC, **Ott BR**, Salloway S, Eds. *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*. Humana Press, Inc., Totowa, NJ, 2004.  
Chapter contributions:  
– D'Abreu A, **Ott BR**. Poststroke Dementia: The Role of Strategic Infarcts, 231-241.  
– Ready RE, **Ott BR**. Quality of Life in Vascular Dementia, 323-329.
28. Ready RE, **Ott BR**, Grace J. Amnesic behavior in dementia: symptoms to assist in early detection and diagnosis. In: *Research and Practice in Alzheimer's Disease and Cognitive Decline*. Vol. 7. B Vellas, M Grundman, H Feldman, LJ Fitten, B Winblad, E Giacobini, eds., Serdi, 2004.
29. **Ott BR**, Lapane KL. Mortality in donepezil treated patients. Letter. *J Am Geriatr Soc* 52(8):1412-1413, 2004.
30. Asadi-Lari M, Tamburini M, Gray D. Patients' needs, satisfaction, and health related quality of life: Towards a comprehensive model. **BR Ott**, Comment in: *Health and Quality of Life Outcomes* 2:32, 2004.
31. Brown LB, **Ott BR**, Papandonatos GD, Ready RE, Morris JC. Who should decide driving competence? Letter. *J Am Geriatr Soc* 53(9):1637-1638, 2005.
32. Festa EK, **Ott BR**, Heindel WC. Alerting and orienting in Alzheimer's disease: A reply. *Neuropsychology* 20(6):757-760, 2006.
33. Tremont G, **Ott BR**. Early-onset Alzheimer's disease. Op-Ed. *Providence Journal*, September 2, 2007.
34. Amick MM, **Ott BR**. Driving safety among older adults. *Med Health RI*, 91(5):145-147, 2008.
35. **Ott BR**, Heindel WC, Papandonatos GD, Festa EK, Davis JD, Daiello LA, Morris JC. A longitudinal study of drivers with Alzheimer disease. Response to letter to the editor. *Neurology* 72:1109-1110, 2009.
36. Carr DB, **Ott BR**. The older driver with cognitive impairment: "It's a very frustrating life." Response to letter to the editor, *JAMA* 304(7): 744-745, 2010.
37. Roth J, **Ott BR**, Gaitanis JN, Blum AS. The Neuroimmunology of Cortical Disease: Dementia, Epilepsy and Autoimmune Encephalopathies. In: *Clinical Neuroimmunology: Multiple Sclerosis and Related Disorders*. Chapter 15, 275-285. SA Rizvi, PK Coyle, Eds., Springer Science, New York, 2011.
38. Cohen RA, Gongvatana W, **Ott BR**. Cerebrospinal fluid biomarkers of neurodegenerative and ventricular brain changes in the elderly. In: *Handbook of Imaging the Alzheimer Brain, Volume 2: Advances in Alzheimer's Disease*. J. W. Ashford, ed., IOS Press, 2011.
39. **Ott BR**. The long and winding road to Alzheimer prevention. *Rhode Island Med J*. 96(4):14-15, 2013. PMID:23641444
40. Afari ME, Blum AS, Mernoff S, **Ott BR**. Driving policy after seizures and unexplained syncope: A practice guide for Rhode Island physicians, *R I Med J*. 91(1):40-43, 2014. PMID:24400312
41. Hali-Tierney AD, **Ott BR**. Driving impairment in older adults. Chapter 29. In: *Geriatric Neurology*. AK Nair and MN Sabbagh, Eds. John Wiley & Sons, Ltd, 2014.
43. Wing E, **Ott BR**. Unilateral greater occipital nerve compression causing scalp numbness. *Rhode Island Med J*,

98(3):34-35, 2015. PMID:26056835

44. Giugliano RP, Sabatine MS, **Ott BR**. Cognitive Function in a Randomized Trial of Evolocumab (Letter). *N Engl J Med*. 377(20):1997, 2017. PMID:2914116

45. Carr DB, **Ott BR**. Heart failure and fitness-to-drive. (Editorial). *J Card Fail*, 26(7):564-565, 2020. PMID:32512216 DOI:<https://doi.org/10.1016/j.cardfail.2020.05.017>

46. **Ott BR**, Daiello LA. Daiello: Remembering the importance of Alzheimer's research during a global pandemic (Op-Ed). *Providence Journal*, June 17, 2020.

#### ELECTRONIC MEDIA PRESENTATIONS:

1. **Ott BR**. A longitudinal study of drivers with Alzheimer disease. Podcast for Neurology, Published: Mon, 31 Mar 2008. <https://www.aan.com/rss/search/home/episodedetail/?item=31>

2. **Ott BR**. Assessing and Modifying Risks for Older Drivers. Video internet presentation for Medscape, sponsored by U.S. Department of Health and Human Services and the National Highway Traffic and Safety Administration, New York, NY, December 3, 2014. [http://www.medscape.org/viewarticle/833915?src=acdm part\\_nhtsa\\_833915](http://www.medscape.org/viewarticle/833915?src=acdm part_nhtsa_833915)

3. **Ott BR**, Knopman D, Jicha G. NeuroPI: Performance Improvement in Neurology, Dementia Module. American Academy of Neurology, 2012, rev. 2016. [http://tools.aan.com/practice/pip/index.cfm?event=module:info&module\\_id=7](http://tools.aan.com/practice/pip/index.cfm?event=module:info&module_id=7)

4. **Ott BR**. An Overview of Diseases that Lead to Cognitive Loss with an Update on Potential New Therapies. WebCam workshop presentation for Course 4, Cognitive Dysfunction, Geriatrics Workforce Enhancement Program, University of Rhode Island, North Kingston, RI, June 29, 2017. <http://web.uri.edu/rigec/about-rigec/>

#### ABSTRACTS

1. Hirano M, **Ott BR**, Raps EC, Lennihan L, Hair LS, Hays AP. Acute steroid myopathy and nondepolarizing blocking agents. *Neurology*. 41(Suppl 1):421, 1991. The 43rd Annual Meeting of the American Academy of Neurology, Boston, April 25, 1991.

2. Fogel BS, **Ott BR**. Measurement of depression in dementia. The 145th Annual Meeting of the American Psychiatric Association, Pittsburgh, May 2-7, 1992.

3. **Ott BR**, Tornabene J, Fogel BS. Deficit awareness in dementia: Relevance to the clinical diagnosis of Alzheimer's disease. *Neurobiol Aging*. 13:( Suppl 1):11, 1992. The Third International Conference on Alzheimer's Disease and Related Disorders, Venice, Italy, July 12-17, 1992.

4. Saver J, **Ott BR**. Unilateral lesions in amnesic stroke. *Neurology*. 43 (Suppl 1): 244,1993. The 45th Annual Meeting of the American Academy of Neurology, New York, April 28, 1993.

5. **Ott BR**, Lafleche G, Whelihan WM, Buongiorno GW, Fogel BS. Unawareness of dementia in Alzheimer's disease. *Neurology* 44(Suppl 2):239-240, 1994. The 46th Annual Meeting of the American Academy of Neurology, Washington, May 4, 1994.

6. **Ott BR**. New treatment options for dementia. *Advances in the Treatment of Neurologic Disorders*, Newport, RI, July 10, 1994.

7. **Ott BR**. Loss of insight in Alzheimer's disease. *APA Symposia #92B*:154, 1995. *New Concepts In the*

Neuropsychiatry Of Motivation symposium, 148th Annual Meeting of the American Psychiatric Association, Miami, May 25, 1995.

8. **Ott BR**, Noto RB, Fogel BS. Apathy and loss of insight in Alzheimer's disease: A SPECT imaging study. *J Neuropsychiatry Clin Neuroscience* 7:422, 1995. The American Neuropsychiatric Association Seventh Annual Meeting, Pittsburgh, PA., October 15, 1995.

9. Whelihan WM, **Ott BR**, Thompson JA. The relationship of neuropsychological executive tests to SPECT measures of frontal lobe functioning in patients with dementia. *Arch Clin Neuropsychology*, 11(5):462-463, 1996. The National Academy of Neuropsychology, 15th Annual Meeting, San Francisco, November 1, 1995.

10. **Ott BR**, Tate CA, Gordon NM, Heindel WC. Gender differences in the behavioral manifestations of Alzheimer's disease. *The Lancet Conference: Dementia 1996*, Edinburgh, Scotland, April 25, 1996,

11. Faberman RS, **Ott BR**, Noto RB, Rogg JM, Hough TJ, Spencer PK, Tung GA. Correlation of white matter hyperintensities on MRI and cortical abnormalities on HMPAO SPECT imaging in Alzheimer's disease. *The American Society of Neuroradiology*, Seattle, June 21, 1996.

12. Faberman RS, **Ott BR**, Noto RB, Rogg JM, Hough TJ, Spencer PK, Tung GA. Correlation between white matter hyperintensities on MRI and cortical perfusion on SPECT imaging in dementia. *Radiology* 201(P):457,1996. The 82nd Scientific Assembly and Annual meeting of the Radiological Society of North America, Chicago, December 1, 1996.

13. **Ott BR**, Noto RB. Functional correlates of driving impairment in patients with dementia. *J Neuropsychiatry Clin Neurosci* 9:175, 1997. The American Neuropsychiatric Association Eighth Annual Meeting, Orlando, FL, February 4, 1997.

14. **Ott BR**, Heindel WC, Whelihan WM, Noto RB. A SPECT imaging study of driving impairment in patients with dementia. *The First Annual Brown University Brain Science Research Day*, Providence, RI, April 3, 1997.

15. Sinha R, Heindel W, **Ott BR**. Classification learning and recognition memory for prototype dot patterns in Alzheimer's disease. *The Society for Neuroscience Annual Meeting*, New Orleans, LA, October 25, 1997.

16. Whelihan WM, Caron M, Piatt A, Noto RB, **Ott BR**, Heindel WC. Neuropsychological predictors of driving ability in early-stage dementia. *The National Academy of Neuropsychology 17th Annual Meeting*, Las Vegas, November 10-13, 1997.

17. **Ott BR**, Heindel WC, Whelihan WM, Noto RB. A SPECT imaging study of driving impairment in patients with dementia. *The Memorial Hospital 65<sup>th</sup> Annual Kenney Day Program*, Pawtucket, RI, February 6, 1998.

18. **Ott BR**, Noto RB, Clements NC. Sensitivity of SPECT for the diagnosis of Alzheimer's disease. *Neurobiol Aging* Vol. 19, No. 4S, S159, 1998. *The Sixth International Conference on Alzheimer's Disease and Related Disorders*, Amsterdam, The Netherlands, July 20, 1998.

19. Abdallah H, **Ott BR**. Brainstem stroke following herpes zoster infection. *The 1999 Rhode Island Regional Conference of the American College of Physicians*, Warwick, RI, April 6, 1999.

20. **Ott BR**, Lapane K, Gambassi G. Gender differences in the behavior problems and treatment of Alzheimer's disease. *Neurology* 52(Suppl 2):396,1999. *The 51<sup>st</sup> meeting of the American Academy of Neurology*, Toronto, Canada, April 22, 1999.

21. Grace J, Boyle P, **Ott BR**, Noto R. Behavioral measurement and SPECT imaging of frontal functioning in

dementia. The 28<sup>th</sup> Annual Meeting of the International Neuropsychological Society, Denver, Colorado, February 9, 2000.

22. **Ott BR**, Heindel WC, Tan Z, Noto RB. Laterality differences in cerebral blood flow between men and women with Alzheimer's disease. The 11<sup>th</sup> Annual Meeting of the American Neuropsychiatric Association, Fort Meyers, Florida, February 20, 2000.

23. Grace J, Zawacki TM, **Ott BR**, Boyle P, Noto R. Behavioral, neuropsychological, and SPECT correlates of frontal lobe functioning in dementia. *Brain and Cognition*, 2000. The 10<sup>th</sup> Annual Rotman Research Institute Conference on the Frontal Lobes, Toronto, Canada, March 20, 2000. *Brain and Cognition* 47(1):279-282, September 2001.

24. Heindel W, Festa-Martino E, **Ott B**. Retrieval from semantic memory: differential effects of aging and Alzheimer's disease. The 7<sup>th</sup> Annual Meeting of the Cognitive Neuroscience Society, San Francisco, April 11, 2000.

25. **Ott BR**, Lapane KL, Owens NJ. Sex hormone drugs and behavioral problems in male nursing home residents. *Neurobiol Aging* 21(1S):238, 2000. The World Alzheimer Congress 2000, Washington, DC, July 12, 2000.

26. Ready RE, **Ott BR**, Grace J, Fernandez I. The Cornell-Brown Scale for quality of life in dementia. The Brown University Department of Psychiatry annual research symposium, February 2001.

27. Naor-Raz G, Heindel W, Tarr M, **Ott B**. Evidence for object recognition impairment in Alzheimer's disease. The 8<sup>th</sup> Annual Meeting of the Cognitive Neuroscience Society, New York, March 25-27, 2001.

28. Festa-Martino E, Heindel W, **Ott B**. Differential effects of aging and Alzheimer's disease on selective attention and arousal. *Inv Ophthalmol Visual Sci (Suppl)*42:S852, 2001. The annual meeting of the Association for Research in Vision and Ophthalmology, New Orleans, April 29-May 4, 2001.

29. Ready RE, **Ott BR**, Grace J, Fernandez I. The Cornell-Brown Scale for quality of life in dementia. *Neurology*. 56 (Suppl 3): 173-174, 2001. The 53<sup>rd</sup> Annual Meeting of the American Academy of Neurology, Philadelphia, May 9, 2001.

30. Ready RE, Grace J, **Ott BR**, Cahn-Weiner D. Behavior change in mild cognitive impairment and dementia. *Arch Clin Neuropsychol* 2001. The National Academy of Neuropsychology, San Francisco, November 1, 2001.

31. Zawacki TM, Grace J, Paul R, Moser DJ, **Ott BR**, Gordon N, Cohen RA. Behavioral problems as predictors of functional abilities of vascular dementia patients. The National Academy of Neuropsychology, San Francisco, November 1, 2001.

32. Ready RE, **Ott BR**, Grace J. Amnesic behavior in dementia: symptoms to assist in early detection and diagnosis. 69<sup>th</sup> Annual Kenney Research Day, Memorial Hospital of Rhode Island, Pawtucket, RI, February 1, 2002.

33. Cahn-Weiner D, Grace J, **Ott B**, Friedman J, Fernandez H. Cognitive and behavioral features of Alzheimer's disease and Parkinson's disease patients. International Neuropsychological Society 30<sup>th</sup> Annual Meeting, Toronto, February 13-16, 2002.

34. Cahn-Weiner D, Malloy PF, Ready R, Grace J, **Ott B**, Rebok G. Preliminary results of a memory training intervention for Alzheimer's disease patients. *J Int Neuropsychol Soc* 2002;8:176. The International Neuropsychological Society 30<sup>th</sup> Annual Meeting, Toronto, February 13-16, 2002.

35. **Ott BR**, Heindel WC, Whelihan WM, Caron MD, Piatt AL, DeCarlo MA. *J Am Geriatric Soc* 2002;50(4):S167.

Maze test performance and reported driving ability in early dementia, 2002 American Geriatrics Society Annual Meeting, Washington, May 8-12, 2002.

– Selected for the Presidential Poster Session

36. Ready RE, **Ott BR**, Grace J. Apathy and depression predict patient and caregiver ratings of quality of life in mild cognitive impairment and Alzheimer's disease. The 8<sup>th</sup> International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 20-25, 2002.

37. Belazi D, Lapane K, **Ott BR**. Estrogen and cognitive decline: A prevention study of women in nursing home facilities. Drug Information Association Fourth Annual Workshop on Pharmaceutical Outcomes Research, Newport, October 17-18, 2002.

38. Ready RE, **Ott BR**, Grace J. Quality of life in mild cognitive impairment and Alzheimer's disease: Discrepancies between caregiver and patient reports. Kenney Research Day Symposium, Memorial Hospital of Rhode Island, Pawtucket, RI, February 7, 2003.

39. Stern RA, Davis JD, Rogers BL, Smith KM, Harrington CJ, **Ott BR**, Prange AJ. A double-blind study of thyroxine in the treatment of Alzheimer's dementia. *J Neuropsychiatry Clin Neurosci*, 15(2):268. 14<sup>th</sup> Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1-4, 2003.

40. Ready RE, **Ott BR**, Grace J. Quality of life in mild cognitive impairment and Alzheimer's disease: Discrepancies between caregiver and patient reports. *J Int Neuropsychol Soc*, 9:226. The International Neuropsychological Society 31<sup>st</sup> Annual Meeting, Honolulu, February 5-8, 2003.

41. Taylor J, Rosenblum J, **Ott B**, Heindel W. Semantic processing and word-stem completion priming in Alzheimer's disease. The International Neuropsychological Society 31<sup>st</sup> Annual Meeting, Honolulu, February 5-8, 2003.

42. Brown LB, Stern RA, Cahn-Weiner DA, Rogers B, Davis MA, Lannon MC, Maxwell C, Souza T, White T, **Ott BR**. The ecological validity of the Neuropsychological Assessment Battery (NAB) driving scenes test. *J Neuropsychiatry Clin Neurosci* 16(2):232-233, 2004. The American Neuropsychiatric Association 15<sup>th</sup> Annual Meeting, Bal Harbour, FLA, February 23, 2004.

43. **Ott BR**, Brown LB, Souza T, Papandonatos GD, Sui Y, Lannon MC, Maxwell C, Morris JC. Prediction of on-road driving performance by patients with mild dementia. *J Neuropsychiatry Clin Neurosci* 16(2):220, 2004. The American Neuropsychiatric Association 15<sup>th</sup> Annual Meeting, Bal Harbour, FLA, February 22, 2004.

44. **Ott BR**, Peskind ER, Pomara N, Potkin SG, McDonald S, Xie Y, Gergel I. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. The 7<sup>th</sup> Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Chicago, April 23, 2004.

45. **Ott BR**, Peskind ER, Pomara N, Potkin SG, McDonald S, Xie Y, Gergel I. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. *J European Neuropsychopharmacol* 14 (suppl 3): S332, 2004. The 17<sup>th</sup> European College of Neuropsychopharmacology Congress, Stockholm, Sweden, October 11, 2004.

46. Ready RE, **Ott BR**, Grace J. Factor Structure of Patient and Informant Ratings on the Dementia Quality of Life Instrument. International Neuropsychological Society 33<sup>rd</sup> Annual Meeting, St. Louis, February 2005.

47. Bhalla R, Stern R, Grace J, **Ott BR**. Alzheimer's disease patients' self-ratings of anxiety before and after an on-road standardized driving test.

– International Neuropsychological Society 33<sup>rd</sup> Annual Meeting, St. Louis, February 2005.

– Brown University Dep. of Psychiatry 10<sup>th</sup> Annual Research Symposium, Providence, April 13, 2006

48. Amick MM, D'Abreu A, Grace J, **Ott BR**. A comparison of on-road driving performance in individuals with Alzheimer's disease and Parkinson's disease. International Neuropsychological Society 33<sup>rd</sup> Annual Meeting, St. Louis, February 2005.
49. Grace J, Amick MM, D'Abreu A, Festa-Martino E, Heindel WC, **Ott BR**. Relationship between neuropsychological tests and on road driving in Parkinson's disease. International Neuropsychological Society 33<sup>rd</sup> Annual Meeting, St. Louis, February 2005.
50. Ready RE, **Ott BR**, Grace J. Insight in mild cognitive impairment and Alzheimer's disease and assessment of quality of life. The 16<sup>th</sup> Annual Meeting of the American Neuropsychiatric Association, Miami, Florida, February 2005.
51. **Ott BR**. Clinician and caregiver assessments of the driving competence of patients with dementia. 72<sup>nd</sup> Annual Kenney Research Day Symposium. Pawtucket, RI, March 4, 2005.
52. Amick M, D'Abreu A, Moro-de-Casillas M, Chou K, **Ott BR**. Excessive daytime sleepiness and on-road driving performance in individuals with Parkinson's disease. The 9<sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, New Orleans, March 5-8, 2005.
53. **Ott BR**, Anthony D, Papandonatos GD, Sui Y, D'Abreu A, Burock J, Curtin A, Wu C-K, Morris JC. Clinician assessment of the driving competence of patients with dementia.  
– American Association of Geriatric Psychiatry 18th Annual Meeting, San Diego, March 3-6, 2005.  
– Neurology 64(Suppl 1):A70, 2005. American Academy of Neurology 57<sup>th</sup> Annual Meeting, Miami, Florida, April 9-16, 2005.
54. Pomara N, **Ott BR**, Peskind E, for the Memantine MEM-MD-10 Study Group. Efficacy of memantine on cognition in mild to moderate Alzheimer's disease.  
– The 12<sup>th</sup> International Congress of the International Psychogeriatric Association, Stockholm, Sweden, September 20-24, 2005.  
– American Academy of Neurology 58<sup>th</sup> Annual Meeting, San Diego, CA, April 1-6, 2006.  
– American Neurological Association 131<sup>st</sup> Annual Meeting, Chicago, October 8, 2006.
55. **Ott BR**, Festa E, Amick M, Grace J, Davis J, Heindel WC. Computerized maze navigation and on-road performance in drivers with dementia. Alzheimer's & Dementia 2(3):S568, 2006. The 10<sup>th</sup> International Conference on Alzheimer's Disease and Related Disorders, Madrid, July 19, 2006.
56. Wu CK, Grace J, **Ott B**. Language-based dementia: Frontotemporal dementia or Alzheimer's disease. The 5<sup>th</sup> International Frontotemporal Dementia Conference, San Francisco, September 6, 2006.
57. Davis JD, Tremont G, **Ott BR**, Festa EK, Heindel WC. Longitudinal analysis of neuropsychological functioning and on-road performance in drivers with mild dementia. The 35<sup>th</sup> Annual Meeting of the International Neuropsychological Society, Portland, February 7-10, 2007.
58. Festa EK, **Ott BR**, Heindel WC. The effect of dual-task engagement on response-selection interference in aging and Alzheimer's disease. Cognitive Neuroscience Society 14<sup>th</sup> Annual Meeting, New York, May 5-8, 2007.
59. Wu CK, Bhalla RK, Grace J, **Ott BR**. Clinical application of MCI diagnosis in a dementia clinic – A study of concordance. Alzheimer's Disease Association International Conference on Prevention of Dementia. Alz Dementia 3(3):S142-143, 2007. Washington, DC, June 9-12, 2007. Alzheimer's & Dementia. 3(3): S142–S143, July 2007.

60. **Ott BR**, Heindel WC, Papandonatos GD, Festa EK, Davis JD, Daiello LA, Morris JC. A longitudinal study of drivers with dementia. The 132<sup>nd</sup> Annual Meeting of the American Neurological Association, Washington, October 7-10, 2007. *Ann Neurology* 62(suppl 11): S22, 2007.  
– Selected for the Dementia Walking Tour
61. Smith MM, Daiello LA, Davis JD, **Ott BR**. Prediction of motor vehicle accidents in older adults enrolled in a study of driving and dementia. The 26<sup>th</sup> Annual National Academy of Neuropsychology Conference, San Antonio, October 25-28, 2007.
62. Daiello LA, **Ott BR**, Festa EK, Heindel WC. Cholinesterase inhibitors improve visual attention in drivers with Alzheimer's disease.  
15th Annual Hospital Research Celebration. Rhode Island Hospital, Providence, RI. November 13, 2007.  
– Awarded First Place in the Lifespan Research Celebration Young Investigators Competition  
The 2008 International Conference on Alzheimer's Disease, Chicago, July 26-31, 2008. *Alzheimer's & Dementia*. 4(4) T498, July 2008.
63. Miller SC, **Ott BR**, Salloway S, Tremont G, Malloy P, Stopa E, Donahue J, Amick M, Grace J, Maguire D. Brown University Dementia Data Repository. Brown University Public Health Program Research Day, Brown University, Providence, RI, April 8, 2008.
64. Daiello LA, **Ott BR**, Lapane KL, Reinert SE, Machan JT, Dore DD. Cholinesterase inhibitor discontinuation is associated with behavioral changes in nursing facility residents with dementia.  
– American Association for Geriatric Psychiatry Annual Meeting, Orlando, March 14-17, 2008.  
– *Alzheimer's & Dementia* 4(Suppl 4):TT498, 2008. The 2008 International Conference on Alzheimer's Disease, Chicago, July 26-31, 2008.
65. Festa EK, Papandonatos GD, **Ott BR**, Heindel WC. Cognitive factors associated with longitudinal decline in driving skills in patients with Alzheimer's disease. *Alzheimer's & Dementia* 4(Suppl 4):T652, 2008. The 2008 International Conference on Alzheimer's Disease, Chicago, July 26-31, 2008.
66. Tremont G, Smith MM, McQuiggan M, Papandonatos G, **Ott BR**. A brief telephone cognitive screen for mild cognitive impairment. *Alzheimer's & Dementia* 4(Suppl 4):T271-272, 2008. The 2008 International Conference on Alzheimer's Disease, Chicago, July 26-31, 2008.
67. Jalbert JJ, Grunier A, **Ott B**, Lapane K. Antipsychotic use in the nursing home: The role of the special care unit. The 24th International Conference for Pharmacoepidemiology & Therapeutic Risk Management. Copenhagen, Denmark, August 17-21, 2008.
68. Heindel WC, Festa EK, Set S, Miller LA, David JD, **Ott BR**. Integrating features across and within cortical streams in visual search: Differential effects of aging and Alzheimer's disease. The 16th Annual Meeting of the Cognitive Neuroscience Society, San Francisco, March 21-24, 2009.
69. Festa EK, Heindel WC, Connors NC, Hirshberg L, **Ott BR**. Neurofeedback training enhances the efficiency of cortical processing in normal aging. The 16th Annual Meeting of the Cognitive Neuroscience Society, San Francisco, March 21-24, 2009.
70. **Ott BR**. Driving assessment of the cognitively impaired older driver. *Int. Psychogeriatrics* 21(Suppl. 2): S18-19, September, 2009.  
– The 21st International Congress of the International Traffic Medicine Association. The Hague, Netherlands, April 28, 2009.  
– The 14th International Congress of the International Psychogeriatric Association, Montreal, September 1-5, 2009
71. Okonkwo O, Tremont G, **Ott BR**. Ventricular size, apolipoprotein E-4, and functional decline in mild cognitive

impairment. Brown University Psychiatry Research Day, March 26, 2009.

72. **Ott BR**, Cohen RA, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD. The relationship between brain ventricular volume and cerebrospinal fluid levels of A-beta and tau in apolipoprotein E4 positive normal controls and patients with Alzheimer's disease

- The 2009 International Conference on Alzheimer's Disease, Vienna, July 11, 2009. *Alzheimer's & Dementia* 5(4): Supplement (July 2009), P299-300
- The 17<sup>th</sup> Annual Hospital Research Celebration

73. Daiello LA, **Ott BR**, Festa EK, Miller L, Heindel WC. Cholinesterase inhibitors improve visual attention in drivers with Alzheimer's disease. 25th Anniversary International Conference on Pharmacoeconomics & Therapeutic Risk Management, Providence, RI. August 16-19, 2009.

74. Stopa E, **Ott BR**, Johanson C, Klinge P, Salloway S, Mernoff S, Stoukides J, DeLaMonte S, Silverberg G, Donahue J, Alvarez V, Geller M. Cognitive improvement after Ventriculo-Peritoneal (VP) shunt placement in Alzheimer's Disease (AD) and non-AD dementia. Hydrocephalus 2009 conference, Baltimore, September 17, 2009.

75. Hill BD, Davis J, **Ott BR**, Alosco M, Noto R, Tremont G. SPECT differences between mild cognitive impairment and Alzheimer's dementia patients. 21<sup>st</sup> Annual Meeting of the American Neuropsychiatric Association, Tampa, March 17-20, 2010.

76. Festa EK, Heindel WC, **Ott BR**. Dual-task conditions modulate the efficiency of selective attention mechanisms in Alzheimer's disease. *Alzheimer's & Dementia* 6(4): S488, 2010. International Conference on Alzheimer's Disease 2010 (ICAD). Honolulu, July 10-15, 2010.

77. Heindel WC, Festa EK, Davis JD, Miller LA, Knott S, **Ott BR**. Differential contributions of selective attention and sensory integration to the decline in driving skill in aging and early Alzheimer's disease. *Alzheimer's & Dementia* 6(4):S128-129, 2010. International Conference on Alzheimer's Disease 2010 (ICAD). Honolulu, July 10-15, 2010.

78. Carr DB, Barco P, Galvin JC, **Ott BR**. Fitness-to-drive in older adults with dementia. *Alzheimer's & Dementia* 6(4):S116, 2010. International Conference on Alzheimer's Disease 2010. Honolulu, July 10-15, 2010. *Alzheimer's & Dementia*. 6(4): S116, July 2010  
-- Featured Research Session.

79. Knott SL, Castro MG, McGinn B, Festa EK, Heindel WC, Davis JD, **Ott BR**. Naturalistic view of the mobility of older drivers with and without cognitive impairment. 16<sup>th</sup> Annual Department of Medicine Research Forum, Brown University, Providence, RI, June 18, 2010.

80. Mikos A, Tremont G, Plourd T, Westervelt H, **Ott BR**. Do patients with mild cognitive impairment demonstrate reduced semantic integrity on animal fluency? The 39<sup>th</sup> Annual Meeting of the International Neuropsychological Society, Boston, MA, February 2-5, 2011.

81. Davis J, Papandonatos GD, Miller LA, Knott S, Festa EK, Heindel WC, Barco P, **Ott BR**. Road test and naturalistic driving behavior in older adults with and without memory loss: Environment matters. The 39<sup>th</sup> Annual Meeting of the International Neuropsychological Society, Boston, MA, February 2, 2011.

82. Tremont G, Papandonatos G, Huminski B, Grace J, Frakey L, **Ott BR**. Use of the Telephone-Administered Minnesota Cognitive Acuity Screen (MCAS) to detect mild cognitive impairment. The 39<sup>th</sup> Annual Meeting of the International Neuropsychological Society, Boston, MA, February 2-5, 2011.

83. Tremont G, Davis J, O'Connor K, Grover C, Bishop D, **Ott B**, Papandonatos G, Fortinsky R. Relationship between expectancy/credibility and early response to telephone-based dementia caregiver interventions. *Alzheimer's & Dementia* 7(4) Suppl 1:S435, 2011. International Conference on Alzheimer's Disease. Paris, July 17-

21, 2011.

84. **Ott BR**, Papandonatos GD, Barco PB, Souza TS, Davis JD, Carr DB. Critical analysis of road test designs for older drivers with cognitive impairment. *Alzheimer's & Dementia* 7(4) Suppl 1:S442, 2011. International Conference on Alzheimer's Disease. Paris, July 17-21, 2011.

85. Festa EK, **Ott BR**, Tremont G, Heindel WC. Neocortical disconnectivity disrupts semantic binding in Alzheimer's disease. *Alzheimer's & Dementia* 7(4) Suppl 1:S242, 2011. International Conference on Alzheimer's Disease. Paris, July 17-21, 2011.

86. Daiello LA, Gongvatana W, Dunsiger S, Cohen R, **Ott BR**. Association of pre-baseline fish oil supplement use with rates of brain atrophy and cognitive decline in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort. *Alzheimer's & Dementia* 7(4) Suppl 1:S606,S590, 2011.

- International Conference on Alzheimer's Disease. Paris, July 17-21, 2011.

- 19th Annual Lifespan Hospital Research Celebration, Providence, October 27, 2011.

- Mind Brain Research Day, Brown University, Providence, March 25, 2014

87. Tremont G, Springate B, Papandonatos G, Huminski B, Grace J, Frakey L, **Ott BR**. The telephone-administered Minnesota Cognitive Acuity Screen (MCAS) is sensitive to conversion from mild cognitive impairment to dementia. *Alzheimer's & Dementia* 7(4) Suppl 1:S547, 2011 International Conference on Alzheimer's Disease. Paris, July 17-21, 2011.

88. Lucas-Carrasco R, Gomez-Benito J, Rejas J, **Ott BR**. The Cornell-Brown scale for quality of life in dementia: Spanish adaptation and validation. International Society for Pharmacoeconomics and Outcomes Research 14<sup>th</sup> Annual European Congress, Madrid, November 5-8, 2011.

89. Alosco ML, **Ott BR**, Spitznagel MB, Cleveland MJ, Royale K, Snyder S, Gunstad J. Impaired knowledge of driving laws independently predicts recommended driving cessation among patients with dementia and cognitive decline. International Neuropsychological Society 40th Annual Meeting. Montreal, February 15-18, 2012.

90. Manning KJ, Davis JD, Hewitt S, **Ott BR**. Empirical evaluation of dementia driving risks proposed by the American Academy of Neurology.

- 19th Annual Lifespan Hospital Research Celebration, Providence, October 27, 2011.

- International Neuropsychological Society 40th Annual Meeting. Montreal, February 15-18, 2012.

91. Festa E, **Ott BR**, Tremont G, Heindel W. Impaired binding of perceptual information within semantic memory in early-stage Alzheimer's disease: Behavioral evidence for disrupted functional connectivity. Cognitive Neuroscience Society Annual Meeting, Chicago, March 31-April 3, 2012.

92. **Ott BR**, Davis JD, Hewitt S, Carr DB. Prediction of road test and naturalistic driving ability of older people with and without cognitive impairment in the office setting. The 64th Annual Meeting of the American Academy of Neurology, New Orleans, April 25, 2012.

-- Selected for the Scientific Highlights session of the top 5% of abstracts.

93. Daniels AH, Daiello LA, Badger J, Born C, Hayda R, **Ott BR**, Szaro J, Cooper MR. Cognitive Assessment After Hip Fracture in the Elderly (CAFÉ): Study Protocol and Selected Baseline Results of a 12-month Prospective Cohort Study. 20<sup>th</sup> Annual Hospital Research Celebration, Rhode Island Hospital, Providence, RI, October 11, 2012.

94. Springate BA, Tremont G, **Ott BR**. Conversion from mild cognitive impairment to dementia is associated with repetitive behaviors. International Neuropsychological Society 41st Annual Meeting, Waikoloa, Hawaii February 6-9, 2013.

95. Tremont G, Springate B, Papandonatos G, Kelley P, Grace J, Frakey L, **Ott BR**. Prediction of conversion from mild cognitive impairment to dementia with the telephone-administered Minnesota Cognitive Acuity Screen.

International Neuropsychological Society 41st Annual Meeting, Waikoloa, Hawaii, February 6-9, 2013.

96. **Ott BR.** Office assessment of the cognitively impaired driver. Symposium presentation: “Trans-disciplinary Approached to the Assessment of Driving Safety: From Teens to the Oldest Old.” International Neuropsychological Society 41<sup>st</sup> Annual Meeting, Waikoloa, Hawaii. February 6-9, 2013.

97. **Ott BR,** Daiello LA, Springate BA, Bixby K, Murali M, Dahabreh IJ, Trikalinos TA. Do statin drugs impair cognition? A systematic review and meta-analysis. *Alzheimer's & Dementia* 9(4):P666, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013  
Mind Brain Research Day, Brown University, Providence, March 25, 2014.

98. **Ott BR,** Grace J, Frakey L, Kelley P, Tremont G. Prediction of functional decline and conversion from mild cognitive impairment with the telephone-administered Minnesota Cognitive Acuity Screen. *Alzheimer's & Dementia.* 9(4): P449, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

99. Tremont G, Davis J, Grover C, Bryant K, **Ott B,** Papandonatos G, Fortinsky R, Gozalo P, Bishop D. Randomized controlled trial of a telephone-delivered intervention (FITT-Caregiver) for dementia caregivers. *Alzheimer's & Dementia* 9(4):P324-325, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

100. Padbury J, Ernerudh J, Sharma S, Stopa E, Kocab J, **Ott B.** Preeclampsia during pregnancy and Alzheimer's disease later in life. *Alzheimer's & Dementia* 9(4):P571, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

101. Heindel WC, Festa EK, **Ott BR,** Sofer I, Serre T. Rapid visual categorization as a sensitive measure of early Alzheimer's disease. *Alzheimer's & Dementia* 9(4):P451–P452, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

102. Festa EK, Katz AP, **Ott BR,** Heindel WC. Perceptual binding of audiovisual speech information is disrupted at the preclinical stage of Alzheimer's disease. *Alzheimer's & Dementia.* 9(4): P452, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

103. Davis JD, Bixby KA, **Ott BR.** Clinician and caregiver prediction of driving competence in older adults who may have early Alzheimer's disease: Validation with road test and naturalistic driving assessments. *Alzheimer's & Dementia* 9(4):P473, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

104. Daiello LA, Daniels AH, Badger J, Lareau CR, Robidoux KA, **Ott BR.** Association of unrecognized preoperative cognitive impairment with postoperative cognitive and functional outcomes in elderly patients awaiting hip fracture repair. Alzheimer's Association International Conference, Boston. July13-18, 2013.

105. Manning KJ, Davis JD, Papandonatos GD, Hewitt SD, **Ott BR.** Clock drawing and driving in aging and dementia: Is it worth the time? *Alzheimer's & Dementia* 9(4):P475, 2013. Alzheimer's Association International Conference, Boston. July13-18, 2013.

106. Barco PB, Carr DB, **Ott BR,** Ice S, Baum C, Roe C. Assessing driving errors in dementia with the Record of Driving Errors (RODE). American Occupational Therapy Association Annual Conference, April 3-6, 2014, Baltimore.

107. Lanata S, Reinert S, Astphan M, **Ott BR.** A survey of mental status examination practices in patients hospitalized for evaluation of altered mental status. 2014 Annual Meeting of the American Academy of Neurology, Philadelphia, April 26-May 3, 2014.

108. Afari ME, Blum AS, Mernoff S, **Ott BR.** Driving policy after seizures and unexplained syncope: A practice guide for RI physicians. Annual Regional Scientific Meeting of the Rhode Island Chapter, American College of

Physicians, Cranston, RI, May 8, 2014.

-- Third place award among 117 abstracts in the Resident/Fellow Forum Competition

109. Snyder PJ, Lim YY, Schindler R, Ott BR, Salloway S, Daiello L, Getter C, Gordon CM. Micro dosing of scopolamine as a “cognitive stress test”: Rationale and test of a very low dose in an at-risk cohort of older adults. *Alzheimer's & Dementia* 10(2):262–67, 2014.

110. Lim YY, Site M, Maruff P, Fernandez B, Salloway S, **Ott BR**, Schindler R, Snyder PJ. Evidence of neuroinflammation in the retina in presymptomatic Alzheimer’s disease. *Alzheimer's & Dementia* 10(4):P429, 2014. Alzheimer’s Association International Conference, July 12-17, 2014, Copenhagen, Denmark.

111. Tremont G, Davis J, Bryant K, **Ott BR**, Papandonatos G, Fortinsky R, Gozalo P, Bishop D. Effect of a telephone-based dementia caregiver intervention on use of community and healthcare resources. *Alzheimer's & Dementia* 10(4):P226-227, 2014. Alzheimer’s Association International Conference, July 12-17, 2014, Copenhagen, Denmark.

112. Alosco ML, Penn MS, Spitznagel MB, **Ott BR**, Cleveland MJ, Gunstad J. Preliminary evidence for the adverse impact of depressive symptoms on driving fitness in older adults with heart failure. International Neuropsychological Society 43<sup>rd</sup> Annual Meeting, Denver, February 4-6, 2015.

113. Thomas J, Luo G, Pelosi M, Davis JD, **Ott, BR**. Using virtual collision judgment assessment to predict driving safety risk in aging and dementia. Rhode Island Alzheimer’s Disease Research Conference. Warwick, RI, March 5, 2015.

114. Hoffman J, **Ott BR**. Clinical outcomes of Florbetapir (18F) PET imaging in patients with cognitive impairment. Rhode Island Chapter American College of Physicians Annual Scientific Meeting. Cranston, RI, May 7, 2015.

115. **Ott BR**, Pelosi MA, Tremont G, Snyder PJ. A survey of knowledge, beliefs and attitudes regarding genetic and amyloid PET status disclosure.

-- Rhode Island Alzheimer’s Disease Research Conference. Warwick, RI, March 5, 2015.

-- Alzheimer’s Association International Conference. Washington, D.C., July 18-23, 2015.

116. **Ott BR**, Bixby K, Davis JD. Video feedback intervention to improve the safety of cognitively impaired older drivers. Alzheimer’s Association International Conference. Washington, D.C., July 18-23, 2015.

117. Stopa EG, Padbury J, Daiello LA, **Ott BR**, Sharma S. Placental tau,  $\alpha$ -synuclein, A $\beta$  and APP levels in pre-eclampsia, and Alzheimer’s disease risk factor. Alzheimer’s Association International Conference. Washington, D.C., July 18-23, 2015. *Alzheimer's & Dementia*. 11(7): P372, July 2015.

118. Daiello LA, Pelosi M, Cizginer S, **Ott BR**. Psychoactive medication use and memory impairment among members of an Alzheimer prevention registry. Alzheimer’s Association International Conference. Washington, D.C., July 18-23, 2015. *Alzheimer's & Dementia*. 11(7): P734, July 2015.

119. Daiello LA, Wellenius G, **Ott BR**, Buka SL. Role of supplemental docosahexaenoic acid (DHA) for cognition in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of randomized controlled trials. Alzheimer’s Association International Conference. Washington, D.C., July 18-23, 2015. *Alzheimer's & Dementia*. 11(7): P611, July 2015.

120. Snyder PJ, Lim YY, Maruff P, Schindler R, **Ott BR**, Salloway S, Noto RB, Yoo DC. Disruption of cholinergic neurotransmission unmasks a $\beta$ -related cognitive impairment in preclinical Alzheimer’s disease. Alzheimer’s Association International Conference. Washington, D.C., July 18-23, 2015. *Alzheimer's & Dementia*, 11(7): P129–P130, July 2015.

121. Figueroa CM, Festa EK, **Ott BR**, Heindel WC. Sensitivity of component attentional measures to subtle cognitive changes and real-world driving performance in early Alzheimer's disease: A longitudinal examination. International Neuropsychological Society 44<sup>th</sup> Annual Meeting, Boston, MA, February 3-6, 2016.  
Brown University Mind Brain Research Day, Providence, RI, March 30, 2016.
122. Ashraf F., **Ott BR**. "Spät-apoplexie," a case of delayed post traumatic intra cerebral hemorrhage. American College of Physicians, RI Chapter Annual Scientific Meeting, Providence, RI, March 30, 2016.
123. **Ott BR**, Jones RN, Noto RB, Yoo DC, Snyder PJ, Bernier JN, Pelosi MA, Carr DB, Roe CM. Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk. Alzheimer's Association International Conference. Toronto, Canada, July 24-28, 2016. *Alzheimer's & Dementia*. 12(7): P1069, July 2016.
124. Roe CM, Barco P, Head DM, Babulal GM, Stout S, Ghoshal N, Selsor N, Vernon EK, Fierberg R, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Holtzman DM, Benzinger T, Fagan AM, **Ott BR**, Carr DB, Morris JC. Preclinical Alzheimer disease predicts longitudinal onset of driving difficulties among cognitively normal persons. Alzheimer's Association International Conference. Toronto, Canada, July 24-28, 2016. *Alzheimer's & Dementia*. 12(7):P1071, July 2016.
125. Daiello LA, Stopa EG, **Ott BR**, de la Monte S, Johanson CE. CNS molecular gradients in mild cognitive impairment and Alzheimer's disease: Implications for blood-brain barrier permeability. Alzheimer's Association International Conference. Toronto, Canada, July 24-28, 2016. *Alzheimer's & Dementia*, 12(7):P1149, 2016.
126. Venkatesan UM, Festa EK, **Ott BR**, Heindel WC. What drives driving: Differences in the relationship of visual search and sensory binding to driving performance between healthy aging and Alzheimer's disease. International Neuropsychological Society 45<sup>th</sup> Annual Meeting, New Orleans, February 1-4, 2017. *J Int Neuropsych Soc* 23(1):230, 2017.
127. Crook C, Papandonatos GD, **Ott BR**, Tremont G. Refining a telephone screening for mild cognitive impairment. International Neuropsychological Society 45<sup>th</sup> Annual Meeting, New Orleans, February 1-4, 2017.
128. Giugliano RP, Mach F, Zavitz K, Keech A, Terje RP, Sabatine MS, Sever PS, Kurtz C, Honarpour N, **Ott BR**, and the EBBINGHAUS Investigators. Primary results of EBBINGHAUS, a cognitive study of patients enrolled in the FOURIER trial. American College of Cardiology 66<sup>th</sup> Annual Meeting, Washington, DC, March 17-19, 2017.
129. Lai LY, Festa EK, Serre T, **Ott BR**, Heindel WC. Rapid visual categorization reveals disrupted ventral stream processing in early Alzheimer's disease. Cognitive Neuroscience Society 24th Annual Meeting. San Francisco, March 25-28, 2017.  
Second Annual Research Meeting of the Rhode Island Alzheimer's Association, Warwick, RI, April 21, 2017.  
-- Best Poster award.
130. Margolis SA, Papandonatos GD, Tremont G, **Ott BR**. Telephone-based Minnesota Cognitive Acuity Screen predicts time to institutionalization and homecare. American Academy of Clinical Neuropsychology Annual Meeting. Boston, June 8-10, 2017.
131. Margolis SA, Tremont G, Denby C, Heller B, **Ott BR**. Subjective cognitive decline in members of the Rhode Island Alzheimer Prevention Registry. Alzheimer's Association International Conference. London, July 16-20, 2017. *Alzheimers Dement* 13(7):P1336, 2017.
132. Santos CY, Johnson LN, Lim YY, Fernandez BM, **Ott BR**, Salloway S, Maruff P, Snyder PJ. Retinal nerve fiber layer and ganglion cell layer volume changes in preclinical Alzheimer's disease over 27 Months. Alzheimer's Association International Conference. London, July 16-20, 2017.  
*Alzheimers Dement* 13(7):P1280, 2017.  
American Neurological Association 142nd Annual Meeting, San Diego, October 15-17, 2017.

133. Snyder PJ, Santos CY, Getter C, Schindler R, **Ott BR**, Salloway S, Yoo DC, Noto RB, Lim YY, Maruff P. Cholinergic deficit as a predictor of disease progression: Amyloid accumulation and episodic memory decline in a 27-month preclinical AD study. Alzheimer's Association International Conference. London, July 16-20, 2017. *Alzheimers Dement* 13(7):P1232-33, 2017.
134. Daiello LA, Jones RN, Stopa E, Grammas P, de la Monte S, Johanson CE, **Ott BR**. Blood-brain barrier gradients in mild cognitive impairment and Alzheimer's disease: Relationship to inflammatory cytokines and chemokines. Alzheimer's Association International Conference. London, July 16-20, 2017. *Alzheimers Dement* 13(7):P640-41, 2017.
135. Roe CM, Babulal GM, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, **Ott BR**, Carr DB, Xiong C, Morris JC. Impact of cognitive reserve and preclinical AD on longitudinal driving performance. Alzheimer's Association International Conference. London, July 16-20, 2017. *Alzheimers Dement* 13(7):P550-51, 2017.
136. Alber J, Silver B, **Ott BR**, Snyder PJ. A potential retinal biomarker of cerebral amyloid angiopathy. Alzheimer's Association International Conference. London, July 16-20, 2017. *Alzheimers Dement* 13(7):P704-705, 2017.
137. Margolis SA, Daiello LA, Tremont G, Heller B, Denby C, **Ott BR**. Age moderates the relationship between drug burden index and subjective cognitive decline in members of the Rhode Island Alzheimer Prevention Registry. National Academy of Neuropsychology 37<sup>th</sup> Annual Conference, Boston, October 26, 2017. *Arch Clin Neuropsychology* 32(6): 656-666, 2017.
138. Margolis SA, Bryant D, Reynolds GO, Denby C, Poll KA, Gilmore M, Tremont G, **Ott BR**. Cognitive decline predicts perceived loneliness in non-demented older adults at risk of Alzheimer's disease. 46<sup>th</sup> Annual Meeting of the International Neuropsychological Society, Washington, February 14-17, 2018.
139. Venkatesan UM, Festa EK, **Ott BR**, Heindel WC. Disentangling deficits in semantic integration and retrieval in aging and Alzheimer's disease. 46th Annual Meeting of the International Neuropsychological Society, Washington, February 14-17, 2018.
140. Margolis SA, Festa EK, Korthauer LE, Gonsalves MA, Oberman L, Heindel WH, **Ott BR**. Repetitive transcranial magnetic stimulation in primary progressive aphasia and behavioral variant frontotemporal dementia: A case series. Alzheimer's Association International Conference. Chicago, July 22-23, 2018.  
-- Selected for special presentation at NPS PIA Scientific Session
141. Reynolds, GO, Margolis SA, Denby C, Poll K, **Ott BR**, Tremont G. Exercise behaviors in older adults: Current habits, willingness to change, and associated barriers/facilitators. Alzheimer's Association International Conference. Chicago, July 23, 2018.
142. Tremont G, Davis J, Britton K, Kenney L, Sanborn V, Uelbecker L, Gillette T, Becker B, **Ott BR**. Initial experience with a yoga intervention for mild cognitive impairment. Alzheimer's Association International Conference. Chicago, July 23, 2018.
143. Drake JD, Daiello LA, Chambers A, **Ott BR**. VCAM-1 as a biomarker of cognitive decline in Alzheimer's disease. Alzheimer's Association International Conference. Chicago, July 23, 2018.
144. Goldfarb D, Snyder PJ, Maruff P, Santos CY, **Ott BR**, Salloway S, Yoo DC, Noto RB, Alber J, Thompson LI, Song A. Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, predicts A $\beta$ -related cognitive impairment in preclinical Alzheimer's disease after a 27 month delay interval. Alzheimer's Association International Conference. Chicago, July 22, 2018. *Alz Dementia* P322, 2018.
145. Alber J, Drake J, Goldfarb D, **Ott BR**, Silver B, Snyder PJ. Retinal changes in cerebral amyloid angiopathy:

Relationship to cerebral pathology. Alzheimer's Association International Conference. Chicago, July 22, 2018.

146. Sofko C, Ahern DC, Davis J, Kenney L, Correia S, **Ott BR**. Ecological validity of a novel scoring method for Trail Making Part B: Application to real-world driving skill.

Brown University Mind-Brain Research Day, Providence, March 25, 2018.

Gerontological Society of America Annual Scientific Meeting, Boston, November 14-18, 2018. *Innov Aging* (2) S1: 687-8, 2018.

147. Karpouzian-Rogers T, Heindel WC, **Ott BR**, Tremont G, Festa EK. Phasic alerting and exogenous attentional orienting in aging and mild cognitive impairment. International Neuropsychological Society Annual Meeting, New York, February 20-23, 2019.

148. Korthauer LE, Lai LY, Tremont G, **Ott BR**, Heindel WC, Festa EK. Amyloid burden is associated with perceptual binding deficits in semantic memory. International Neuropsychological Society Annual Meeting, New York, February 20-23, 2019.

149. Roe CM, Stout SH, Rajasekar G, Ances BM, Jones JM, Head D, Benzinger TLS, Williams MM, Davis JD, **Ott BR**, Warren DK, Babulal GM. A 2.5 year longitudinal assessment of naturalistic driving in preclinical Alzheimer disease. Alzheimer's Association International Conference. Los Angeles, July 14-18, 2019.

150. Santos CY, Getter C, Stoukides J, **Ott BR**, Salloway S, Renehan W, Grammas P. Clinical trial design for a pilot study evaluating thrombin inhibition in Alzheimer's disease. Alzheimer's Association International Conference. Los Angeles, July 14-18, 2019.

151. Gencer B, Sabatine MS, Mach F, Guo J, Im K, **Ott BR**, Giugliano RP. Impact of lowering LDL-C with evolocumab on everyday cognition in 22,655 participants from the FOURIER trial. American Heart Association Annual Meeting, Philadelphia, November 16, 2019.

152. Drake JD, Chambers AB, **Ott BR**, Daiello LA. Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in Alzheimer's disease. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

153. Daiello LA, **Ott BR**, Jones R. Blood-brain barrier dysfunction and perioperative neurocognitive disorders: Cognitive Recovery After Elective Surgery (CREATES) study design and methods. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

154. Korthauer LE, Denby C, Molina D, Wanjiku J, Daiello LA, Drake J, Grill JD, **Ott BR**. Implementation of a targeted screening program for Alzheimer's disease risk in a primary care setting. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

155. Festa EK, He M., Korthauer LE, **Ott BR**, Heindel WC. Light- and task-induced pupillary responses as indirect markers of cholinergic and noradrenergic function in patients with amnesic mild cognitive impairment. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

156. Tremont G, Davis JD, Britton K, Kenney L, Sanborn V, Uebelacker L, **Ott BR**. A pilot trial of a yoga intervention versus healthy living education for mild cognitive impairment. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

157. **Ott BR**, Papandonatos GD, Burke EM, Erdman D, Carr DB, Davis JD. A video feedback intervention for cognitively impaired older drivers. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

158. Korthauer LE, Giugliano RP, Guo J, Sabatine MS, Sever PS, Keech A, Pedersen TR, Ruff C, Mach F, **Ott BR**. Association of ApoE genotype and lipid lowering with cognitive function in a randomized placebo-controlled trial

of evolocumab. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2020.

159. Maynard T, Frink T, Mankodiya K, Davis J, **Ott BR**, Uebelacker L, Tremont G. Initial translation of a dementia caregiver intervention into a mobile health application. Gerontological Society of America Annual Scientific Meeting. Philadelphia, November 4-8, 2020.

160. Luo G, Moharrer M, Davis J, **Ott BR**. Which is more important for driving: Eye or brain? The Eye, The Brain & The Auto 9th World Research Congress on Health and Modern Mobility. Detroit, December 7-8, 2020.

161. Sullivan KL, Davis JD, Hallowell ES, Tremont GN, Daiello LA, **Ott BR**, Burke E, Nakhutina L, Margolis SA. Compensatory strategy use in mild cognitive impairment. International Neuropsychological Society meeting. San Diego, February 3-6, 2021.

162. Karstens AJ, Tiboni H, Maynard T, Tremont G, **Ott BR**. Feasibility of a remote cognitive and dietary assessment during the COVID-19 outbreak. International Neuropsychological Society meeting. San Diego, February 3-6, 2021.

163. Kelly DA, Davis JD, Daiello LA, Burke E, Fernandez T, Tremont GN, **Ott BR**, Margolis SA. Neuroticism moderates the association between beliefs about medications and reported adverse medication effects in mild cognitive impairment. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2021.

164. Maynard T, Chapman K, Sadhu S, Frink T, Mankodiya K, Uebelacker L, **Ott BR**, Tremont G. Beta test of a mobile health application for dementia caregivers. Alzheimer's Association International Conference. Amsterdam, July 26-30, 2021.

165. Alcusky M, Lapane K, Tija J, **Ott BR**. Patterns of antedementia and antipsychotic medication use before and after nursing home admission among residents with Alzheimer's disease. International Society for Pharmacoepidemiology 37<sup>th</sup> Annual Conference. Berlin, August 26-30, 2021

#### INVITED PRESENTATIONS:

1. Diagnosis and treatment of Alzheimer's disease. Medical grand rounds, Harrington Memorial Hospital, Southbridge, MA, October 4, 1990.

2. New treatment options for dementia. Advances in the Treatment of Neurologic Disorders symposium; Newport, RI, July 10, 1994.

3. Diagnosis and management of Alzheimer's disease. Brown University Center for Gerontology and Health Care Research, Providence, RI, January 31, 1995.

4. Loss of insight in Alzheimer's disease. Presented at New Concepts in the Neuropsychiatry of Motivation symposium, 148<sup>th</sup> Annual Meeting of the American Psychiatric Association, Miami, Florida, May 25, 1995.

5. Update on Research and Medical Advances in Alzheimer's Disease. Taking Control: A Symposium Focusing on Chronic Conditions and Disabilities. University of Rhode Island, Providence, RI, October 26, 1996.

6. Alzheimer's Disease: Research Update. Alzheimer's Association Chapter Annual Meeting, Roger Williams Hospital, June 20, 1996.

7. Overview of Alzheimer's disease. American Association of Neuroscience Nurses chapter conference, Randolph, MA, 1997.

8. Promotions and faculty development panel. Faculty Development Workshop, Brown University, Providence, RI, March 27, 1997.

9. Treatments for dementia. Alzheimer's Association Fifth Annual Caregiver Conference, Warwick, RI, April 24, 1997.
10. Alzheimer's disease. Neurology Grand Rounds, St. Vincent's Hospital, Worcester, MA, May 8, 1997.
11. Pieces of the ethical puzzle. Alzheimer's Association Regional I and II Meeting, Providence, RI, June 14, 1997.
12. New Approaches to the Treatment of Alzheimer's Disease. Dementia Update for Healthcare Professionals -- Second Annual Alzheimer's Association Interdisciplinary Conference, Providence, RI, November 4, 1997.
13. Driving Assessment in the Elderly. Rhode Island Monthly Geriatric Seminars, Providence, RI, November 19, 1997.
14. What Caregivers Really Want To Know About Research, panelist. Alzheimer's Association Rhode Island Chapter Sixth Annual Caregiver's Conference, Cranston, RI, April 28, 1998.
15. The Ethical Challenges of Alzheimer's Disease, panelist. The Seventh National Alzheimer's Disease Education Conference, Indianapolis, Indiana, July 27, 1998.
16. Complementary and alternative medicines for Alzheimer's disease. Seventh Annual Statewide Conference. RI Chapter of the Alzheimer's Association. Cranston, RI, April 28, 1999.
17. Driving and dementia workshop. 8<sup>th</sup> Annual Statewide Conference, RI Chapter of the Alzheimer's Association, Warwick, RI April 25, 2000.
18. Complementary and alternative medicines for Alzheimer's disease. "A Map Through the Maze," annual statewide conference, Massachusetts Chapter of the Alzheimer's Association, Marlborough, MA, May 10, 2000.
19. Alzheimer's: A treatable disease. Medicine Grand Rounds, Waltham Deaconess Hospital, Waltham, MA, May 31, 2000.
20. Sex hormone drug effects on men with dementia. Alzheimer's Disease Research Conference. Memorial Hospital, Pawtucket, RI, September 8, 2000.
21. Driving and neurologic disorders. Medical Grand Rounds, Memorial Hospital of Rhode Island, Pawtucket, RI, September 27, 2000.
22. Sex hormone drug effects on men with dementia, case presentation. Neurology Grand Rounds, Rhode Island Hospital, Providence, RI, October 4, 2000.
23. Alzheimer's: A treatable disease. Medical Grand Rounds. St. Luke's Hospital, New Bedford, MA, November 7, 2000.
24. A longitudinal study of hazardous drivers with dementia. Faculty research meeting, Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, RI, January 9, 2001.
25. Clinical appraisal of anti-dementia therapy. Geriatric Psychiatry Conference. Butler Hospital, Providence, RI, January 18, 2001.
26. Frontal lobe dementia with motor neuron disease, case presentation. Neurology Grand Rounds, Rhode Island Hospital, Providence, RI, July 11, 2001.
27. Update on Alzheimer's disease. Rhode Island Society of Osteopathic Physicians and Surgeons annual meeting.

Newport, RI, August 24, 2001.

28. Update on Alzheimer's disease. Medical Grand Rounds, Memorial Hospital of Rhode Island, Pawtucket, RI, September 26, 2001.

29. Stroke. Family Medicine Conference, Memorial Hospital of Rhode Island, Pawtucket, RI, September 27, 2001.

30. Memory disorders and their treatment. Fifth Annual Symposium, American Academy of Physician Assistants, Pawtucket, RI, November 3, 2001.

31. Mild cognitive impairment. Neurology Grand Rounds, case presentation, Rhode Island Hospital, Providence, RI, June 12, 2002.

32. Cholinesterase inhibitors in the long-term care of Alzheimer's disease. Second Annual Long Term Care Symposium, Warwick, RI, June 14, 2002.

33. Drivers with dementia. Neurology Grand Rounds, Rhode Island Hospital, Providence, RI, September 4, 2002.

34. Mild cognitive impairment. Geriatric Psychiatry Conference. Butler Hospital, Providence, RI, January 16, 2003.

35. Research Update. Alzheimer's Disease Forum. Brown University, Providence, RI, May 6, 2003.

36. Driving and dementia. Geriatric Psychiatry conference, Butler Hospital, Providence, RI, November 6, 2003

37. Long term management of Alzheimer's disease. Medical Staff Conference, The Westerly Hospital, Westerly, RI, December 4, 2003.

38. Stroke Update. Family Medicine Conference, Memorial Hospital of Rhode Island, Pawtucket, RI, December 5, 2003.

39. Orthostatic tremor and the aging nervous system. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, March 3, 2004.

40. Gender differences in the treatment of Alzheimer's disease. Alzheimer's Disease 2004, Tulsa OK, March 5, 2004.

41. Driving and dementia research. Boston University Alzheimer's Disease Center Seminar, Boston University School of Medicine, Boston, MA, March 10, 2004.

42. Alzheimer Research Panel. Alzheimer's Association Rhode Island Chapter Eleventh Annual Caregiver's Conference, Warwick, RI, April 28, 2004.

43. Advances in the treatment of Alzheimer's disease. Academy of Family Physicians Annual Conference, Newport, RI, May 22, 2004.

44. The cognitively impaired physician. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, November 10, 2004.

45. Driving and dementia. Monthly Research Forum, Memorial Hospital of Rhode Island, Pawtucket, RI, May 10, 2005.

46. Arachnoid cysts and dementia. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, June 29, 2005.

47. Diagnosis and treatment of early Alzheimer's disease 2005. Medical Grand Rounds, Memorial Hospital of Rhode Island, Pawtucket, RI, September 14, 2005.
48. Progress in research on driving and dementia. Dementia research meeting, Rhode Island Hospital, Providence, RI, April 26, 2006
49. Mild cognitive impairment. The Alzheimer Partnership of Bristol County, Marshfield, MA, May 17, 2006.
50. Drivers with dementia. Monthly Research Meeting, Boston University Alzheimer's Disease Center, Boston, MA, June 14, 2006.
51. Drivers with dementia. Monthly Research Meeting, Washington University Alzheimer's Disease Research Center, St. Louis, MO, August 29, 2006.
52. Drivers with dementia. Dementia and Neuropsychiatry regional conference, University of Vermont, Burlington, VT, September 16, 2006.
53. Hereditary frontotemporal dementia due to progranulin mutation. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, January 10, 2007.
54. Identification of hazardous drivers with dementia. Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Vision, Aging, and the Brain session, Fort Lauderdale, FLA, May 5, 2007.
55. Alzheimer's Disease – Early diagnosis, current treatments and investigational therapies. National Alzheimer's Association Clinical Studies Initiative. Providence, RI, May 22, 2007.
56. The changing treatment paradigm in Alzheimer's disease. Grand Rounds, Manchester VA Hospital, Manchester, NH, May 25, 2007.
57. Diagnosis and behavioral management of Alzheimer's disease and other dementias. Glennan Center for Geriatrics, Eastern Virginia Medical School, Norfolk, VA, June 1, 2007.
58. Diagnosis and treatment of cognitive impairment in the elderly. American College of Physicians, Rhode Island Chapter Scientific Meeting. Newport, RI, October 10, 2007.
59. Driving in the elderly. Neurology of the Elderly Symposium, Warren Alpert Medical School of Brown University. Providence, RI, November 3, 2007.
60. Hashimoto's encephalopathy. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, January 28, 2008.
61. A longitudinal study of drivers with Alzheimer disease. Podcast for *Neurology*, Published: Mon, 31 Mar 2008 15:03:36 GMT
62. Driving evaluations in cognitively impaired older adults. Eighth Annual Friedman Conference. Washington University, St. Louis, May 13, 2008.
63. Early onset dementia. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, October 1, 2008.
64. Driving evaluations in cognitively impaired older adults. Geriatric Psychiatry Conference. Butler Hospital, Providence, RI, October 2, 2008.
65. Driving assessment of the cognitively impaired older driver. 21st International Congress of the International

- Traffic Medicine Association. The Hague, Netherlands, April 28, 2009.
66. Post lumbar puncture epidural hematoma. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, July 21, 2009.
67. Path to Prevention Symposium. Driving assessment of the cognitively impaired older driver. International Psychogeriatric Association 14<sup>th</sup> International Congress, Montreal, September 2, 2009.
68. Driving impairment in early Alzheimer's disease. Assessment of Cognition in Early Dementia. NIH Workshop, Bethesda, March 31, 2010.
86. The older driver with cognitive impairment: "It's a very frustrating life." Teleconference sponsored by the Institute for Healthcare Improvement in partnership with JAMA, June 16, 2010.
87. New research diagnostic criteria for Alzheimer's disease, mild cognitive impairment, and pre-clinical Alzheimer's disease. Alzheimer's Disease & Memory Disorders Center research meeting, Rhode Island Hospital, Providence, RI, September 29, 2010.
71. Incipient Alzheimer's disease and motor vehicle crashes. Collaborative Research Workshop, Brown University Department of Engineering and Lifespan Hospital System, Providence, RI, December 9, 2010.
72. Diagnosis and treatment of Alzheimer's disease. Update 2011. Medical Grand Rounds, Rhode Island Hospital, Providence, RI, April 5, 2011.
73. Diagnosis and treatment of Alzheimer's disease. Update 2011. Case Management Society of New England. Warwick, RI, May 5, 2011.
74. Diagnosis and treatment of Alzheimer's disease. Update 2011. Newport Hospital Medical Grand Rounds, Newport Hospital, Newport, RI, June 3, 2011.
75. Validation of screening and road tests for older drivers in the "real world." Washington University, St. Louis, MO, June 6, 2011.
76. A case of rapidly progressive dementia. Neurology Grand Rounds, Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, September 14, 2011.
77. Driving under the influence of aging and cognitive impairment. Miriam Hospital Be Safe This Fall Annual Meeting. Providence, RI, October 28, 2011.
78. Symposium: Clinical assessment of the cognitively impaired older driver. National Academy of Neuropsychology 31<sup>st</sup> Annual Conference, Marco Island, FL, November 18, 2011.
79. Naturalistic assessment of cognitively impaired older drivers. Vision and Visual Optics seminar, Schepens Research Institute, Boston, MA, November 29, 2011.
80. A case of frontal variant Alzheimer's disease. Neuropathology Rounds, Rhode Island Hospital, Providence, RI, January 11, 2012.
81. The borderland of Alzheimer's disease and hydrocephalus. Neurology Grand Rounds, Rhode Island Hospital, Providence, RI, January 18, 2012.
82. Driving under the influence of aging and dementia. New Directions in Research and Care, 2012 Education and Research Conference, Keynote address, Greater New Jersey Chapter of the Alzheimer's Association, Somerset, NJ, May 10 and 11, 2012.

83. Meeting the need to treat Alzheimer's disease. The Norman Prince Neurosciences Institute Inaugural Symposium panel discussion. Alpert Medical School of Brown University, Providence, RI, June 8, 2012.
84. Driving under the influence of aging and dementia. Annual Caregiver and Healthcare Professional Conference, Rhode Island Chapter of the Alzheimer's Association, Warwick, RI, June 27, 2012.
85. Office assessment of the cognitively impaired driver. Symposium presentation: "Trans-disciplinary Approached to the Assessment of Driving Safety: From Teens to the Oldest Old." International Neuropsychological Society 41<sup>st</sup> Annual Meeting, Waikoloa, Hawaii. February 6-9, 2013.
86. Update on Alzheimer's disease, 2012-2013. Department of Medicine Grand Rounds, Rhode Island Hospital, Providence, RI, April 2, 2013.
87. Pseudobulbar affect. Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, May 29, 2013.
88. New directions in the diagnosis and treatment of mild cognitive impairment and early Alzheimer's disease. Annual Caregiver and Healthcare Professional Conference, Rhode Island Chapter of the Alzheimer's Association. Warwick, RI, June 25, 2013.
89. Road test and naturalistic driving performance in healthy and cognitively impaired older adults: Does environment matter? 6<sup>th</sup> Biennial World Research Congress of The Eye, The Brain, & The Auto. The Detroit Institute of Ophthalmology, Dearborn, MI, September 18, 2013.
90. Driving under the influence of aging and dementia. Annual Capone Family Aging Lecture. Butler Hospital, Providence, RI, November 16, 2013.
91. Oppenheimer Brownell variant of Creutzfeldt Jacob disease. Neurology Morbidity and Mortality Rounds, Rhode Island Hospital, Providence, RI, March 12, 2014.
92. Frontotemporal dementia: An untreatable illness? Neurology Grand Rounds, case discussion, Rhode Island Hospital, Providence, RI, April 23, 2014.
93. Alzheimer's Disease Awareness, panel discussion. Brown University, Providence, RI, April 25, 2014.
94. Assessing and Modifying Risks for Older Drivers. Video internet presentation for Medscape, sponsored by National Highway Traffic and Safety Administration, New York, NY, May 21, 2014.
95. Symposium on Alzheimer's disease, panel discussion. Norman Prince Neurosciences Institute, Providence, RI, September 23, 2014.
96. Performance improvement in dementia care. Neurology Grand Rounds, Rhode Island Hospital, Providence, RI, February 24, 2015.
97. Alzheimer's disease research in Rhode Island: Speaker and moderator. Rhode Island Alzheimer's Disease Research Conference. Warwick, RI, March 5, 2015.
98. Frontotemporal Dementia. Alzheimer's Association Caregivers Conference. Warwick, RI, March 5, 2015.
99. Identifying medically at risk drivers. Older Drivers Safety Summit. University of Massachusetts, Boston, MA, June 16, 2015.
100. Semantic dementia: A form of primary progressive aphasia. Neurology Grand Rounds, case discussion, Rhode

Island Hospital, Providence, RI, October 7, 2015.

101. Early diagnosis and treatment of Alzheimer's disease. Neurology Update 2015 CME program. Alpert Medical School of Brown University, Providence, RI, November 7, 2016.

102. Statins and their effects on cognition. Aging and Dementia Research Program. Rhode Island Hospital, Providence, RI, November 30, 2016.

103. Intracerebral hemorrhage and anticoagulation in a patient with amyloid angiopathy and lymphoma. Morbidity and Mortality, panel discussion. Rhode Island Hospital, Providence, RI, January 11, 2017.

104. Statins and the brain: Friend or foe? Neurology Grand Rounds. Rhode Island Hospital, Providence, RI, January 18, 2017.

105. Driving under the influence of aging and dementia. University of California, Irvine, MIND 28th Annual Southern California Alzheimer's Disease Research Conference, Irvine, CA, September 22, 2017.

106. Countdown to 2025: Progress on ending Alzheimer's disease. Newport Hospital, Newport, RI, December 7, 2017.

107. Countdown to 2025: Progress on ending Alzheimer's disease. 26<sup>th</sup> Annual Primary Care Conference of the Rhode Island Chapter of the American Academy of Family Physicians, Alpert Medical School of Brown University, Providence, RI, March 24, 2018.

108. Countdown to 2025: Progress on ending Alzheimer's disease. Miriam Hospital, Providence, RI, April 19, 2018.

109. Naturalistic driving research in aging and dementia. Washington University ADRC Research Conference, St. Louis, May 15, 2018.

110. Countdown to 2025: Progress on ending Alzheimer's disease. University of Rhode Island, Kingston, RI, October 18, 2018.

111. Statins and the brain: Friend or foe? Neurology Grand Rounds, Southern Illinois University, Springfield, IL, November 7, 2018.

112. Research partnerships with minority communities: Applying these concepts in Rhode Island, Moderator. Lieutenant Governor's Alzheimer's & Dementia Research Funding Forum, Warwick, RI, December 17, 2018.

113. Inflammatory amyloid angiopathy. Morbidity and Mortality conference. Rhode Island Hospital, Providence, RI, January 10, 2019.

114. Transcranial magnetic stimulation in Alzheimer's disease and related disorders. Rhode Island Alzheimer's Disease Research Conference. Warwick, RI, April 25, 2019.

115. Frontotemporal degeneration: A treatable dementia? Neurology Grand Rounds. Rhode Island Hospital, Providence, RI, July 31, 2019.

#### GRANTS & CLINICAL RESEARCH:

1. #970-26 1990-1994  
Parke-Davis Pharmaceutical Co.  
Double-blind, placebo-controlled, parallel group, multicenter study of tacrine in Alzheimer's disease patients. This study is to determine safety and efficacy of tacrine for the treatment of Alzheimer's disease. (phase III)

Role: Site PI

2. #996-019/025 1991-1993  
DuPont Merck Pharmaceutical Co.  
Randomized placebo-controlled study of DUP-996 (linopirdine) in patients with mild to moderate dementia of the Alzheimer type.  
This study is to determine safety and efficacy of linopirdine for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI
3. Surdna Foundation Grant Ott (PI) 1991-1993  
Brown University Center for Gerontology and Health Care Research  
Awareness of deficit in Alzheimer's disease.  
This study is to examine the psychological and physiological substrate of deficit awareness in patients with Alzheimer's disease.  
Role: PI
4. #303 1993-1994  
Hoechst-Roussel Pharmaceuticals, Inc.  
Multicenter, 24-week, double-blind, parallel group safety, tolerance and efficacy comparison of placebo and HP 029 (velnacrine maleate) in outpatients with Alzheimer's disease.  
This study is to determine safety and efficacy of velnacrine for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI
5. #159-103 1994-1996  
Pfizer, Inc.  
A randomized, double-blind, placebo-controlled study of the safety and efficacy of three doses of CP-118,954 administered for 12 weeks to subjects with Alzheimer's disease.  
This study is to determine safety and efficacy of CP-118,954 for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI
6. #D94-029 1995-1998  
Miles/Bayer Inc.  
A double blind, placebo-controlled, multicenter pilot study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer's disease (phase II)  
This study is to determine safety and efficacy of metrifonate for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI
7. #D95-018 1995-1998  
Bayer Corp.  
A double blind, placebo controlled trial to evaluate the safety and efficacy of metrifonate (BAY A 9826) in patients with probable Alzheimer's disease.  
This study is to determine safety and efficacy of metrifonate for the treatment of Alzheimer's disease. (phase III)  
Role: Site PI
8. #E2020-A001-312 1996-1997  
Eisai America, Inc.  
A 54-week, randomized, double-blind, placebo-controlled evaluation of the effects of donepezil hydrochloride (E2020) on functional outcomes in patients with Alzheimer's disease with a staged crossover to open-label donepezil hydrochloride.  
This study is to determine safety and efficacy of donepezil for the treatment of Alzheimer's disease. (phase IIIB)  
Role: Site PI
9. UO1 #AG10483 Leon Thal (PI) 1996-1998  
NIH/NIA/ADCS Mulnard (Project director)

A multicenter, double-blind, placebo-controlled study of estrogen replacement therapy in patients with mild to moderate Alzheimer's disease: A pilot study of the Alzheimer's Disease Cooperative Study (ADCS).  
This study is to determine safety and efficacy of estrogen for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI

11. # CV-2619/PNFP-001 1997-1999  
Takeda America, Inc.  
A randomized, double-blind, placebo-controlled, twelve-month safety and efficacy trial of 120, 240, and 360 mg tid of Idebenone (CV-2619) in patients with probable Alzheimer's disease.  
This study is to determine safety and efficacy of donepezil for the treatment of Alzheimer's disease. (phase III)  
Role: Site PI

12. BAY a 9826/D97-019 1997-1998  
Bayer Corp.  
Metrifonate investigational nationwide trial.  
This study is to determine safety and efficacy of metrifonate for the treatment of Alzheimer's disease. (phase IIIB)  
Role: Site PI

13. U01 #AG10483 Thal (PI) 1998-2000  
NIH/NIA/ADCS Singer (Project director)  
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.  
This study is to determine safety and efficacy of melatonin for the treatment of sleep disturbance in Alzheimer's disease. (phase IV)  
Role: Site PI

14. #FA-960-0002 1999-2000  
Fujisawa Research Institute of America  
A randomized, double-blind, placebo-controlled study to determine the safety and efficacy of FK960 in patients with mild to moderate probable Alzheimer's disease.  
This study is to determine safety and efficacy of FK960 for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI

15. #082-99-003 1999-2000  
NeoTherapeutics, Inc.  
A multicenter, randomized, double-blind, placebo-controlled study to evaluate AIT-082 in patients with probable Alzheimer's disease of mild to moderate severity.  
This study is to determine safety and efficacy of FK960 for the treatment of Alzheimer's disease. (phase II)  
Role: Site PI

16. PRG-1837 Cahn-Weiner (PI) 10/1/99-12/31/01  
Alzheimer's Association  
Combined behavioral and pharmacologic intervention to improve memory in Alzheimer's disease.  
This study is to determine the efficacy of a memory training program for patients with mild Alzheimer's disease.  
Role: Co-investigator

17. U01 #AG10483 Thal (PI) 1999-2001  
NIH/NIA/ADCS Aisen (Project director)  
A multicenter trial of rofecoxib and naproxen in Alzheimer's disease.  
This study is to determine safety and efficacy of non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. (Phase IIB)  
Role: Site PI

18. #082-2001-001 2001-2002  
 NeoTherapeutics, Inc.  
 A placebo-controlled dose-titration efficacy and tolerability study of Neotrofin™ in patients with probable Alzheimer's disease.  
 This study is to determine safety and efficacy of Neotrofin for the treatment of Alzheimer's disease. (Phase IIB)  
 Role: Site PI
19. IRG-99-1668 Stern (PI) 7/1/99-1/31/03  
 Alzheimer's Association  
 A double-blind study of donepezil with and without thyroid hormone in the treatment of Alzheimer's dementia.  
 This study is to determine safety and efficacy of low dosage thyroid hormone for the treatment of Alzheimer's disease. (Phase II)  
 Role: Consultant
20. U01 #AG10483 Thal (PI) 1998-2003  
 NIH/NIA/ADCS Peterson (Project director)  
 A randomized, double-blind, placebo-controlled trial of vitamin E and Aricept to prevent clinical progression from mild cognitive impairment (MCI) to Alzheimer's Disease (AD).  
 This study is to determine safety and efficacy of donepezil and vitamin E in preventing conversion to dementia among subjects with mild cognitive impairment. (Phase III)  
 Role: Site PI
21. NO1 #WH-32119 Shumaker (PI) 6/1/96-3/1/05  
 NIH/NHLBI Assaf (Site PI)  
 The effects of hormone therapy on the development and progression of dementia (The Women's Health Initiative Memory Study)  
 This study is to determine safety and efficacy of estrogen hormone replacement therapy in preventing conversion to dementia among post menopausal women. (Phase III)  
 Role: Site Phase 3 clinician/co-investigator
22. RO1 #AG15375 Heindel (PI) 4/1/99-3/31/04  
 NIH/NIA  
 Arousal, attention, and priming in Alzheimer's disease.  
 This study is to understand attention related cognitive deficits and their role in memory dysfunction in patients with Alzheimer's disease.  
 Role: Co-investigator (5%)
23. MEM-MD-10+11 2001-2003  
 Forest Laboratories, Inc.  
 A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer's type.  
 This study is to determine safety and efficacy of memantine for the treatment of Alzheimer's disease. (Phase III)  
 Role: Site PI
24. F32 #AG20008 Ready (PI) 7/1/01-6/30/03  
 NIH/NIA  
 Quality of life in cognitively impaired elderly.  
 This research fellowship is to understand and develop assessment instruments for quality of life in dementia.  
 Role: Sponsor/mentor
25. Ittleson Foundation Ott (PI) 7/16/01-2004  
 Memory and attentional functional MRI activation in mild cognitive impairment patients treated with donepezil.  
 This pilot study is to examine changes in functional MRI related to treatment with donepezil in patients with mild cognitive impairment.

Role: PI

26. MEM-MD-12

5/1/02-2003

Forest Laboratories, Inc.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer's type.

This study is to determine safety and efficacy of memantine combined with a cholinesterase inhibitor for the treatment of Alzheimer's disease. (Phase III)

Role: Site PI

27. NER-MD-01

2/4/03-2004

Forest Laboratories, Inc.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of neramexane in patients with moderate to severe dementia of the Alzheimer's type.

This study is to determine safety and efficacy of neramexane for the treatment of Alzheimer's disease in addition to a cholinesterase inhibitor. (Phase II)

Role: Site PI

28. R21 #MH62561

Tremont (PI)

12/01/01-11/30/04

A telephone intervention for dementia caregivers.

This study is to develop a telephone intervention for dementia caregivers.

Role: Consultant

29. U01 #AG10483

Thal (PI)

1/15/02-2/28/07

NIH/NIA/ADCS

Ferris (Project director)

Assessment measures for AD primary prevention trials.

This study is to develop telephone and mail-in instruments for use in AD primary prevention trials.

Role: Site PI

30. U01 #AG10483

Thal (PI)

2/10/03-6/30/07

NIH/NIA/ADCS

Aisen (Project director)

High dose supplements to reduce homocysteine and slow the rate of cognitive decline in Alzheimer's disease.

This study is to determine the efficacy of folate, vitamin B6, and vitamin B12 in slowing the progression of Alzheimer's disease. (Phase III)

Role: Site PI

31. Brown University Fund

Heindel (PI)

6/12/03-2005

Center for Translational Brain Research

Sensory integration deficits as cognitive markers of cortical disconnection.

This study is to investigate the utility of sensory integration as a marker for early detection and progression of AD.

Role: Co-investigator

32. Investigator Initiated Grant

Heindel (PI)

9/1/03-8/30/06

Alzheimer's Association

Behavioral and electrophysiological investigation of semantic memory in Alzheimer's disease.

This study is to examine the relationships between semantic deficits in Alzheimer's disease and attention using electrophysiological event-related potentials.

Role: Co-investigator

33. 1R01 #AG016335 Ott (PI) 9/15/01-4/30/07  
 NIH/NIA  
 A longitudinal study of hazardous drivers with dementia.  
 This study is to define the course of driving impairment in Alzheimer's disease and develop computerized test predictors of impaired road test performance.  
 Role: PI (30%)
34. U01 #AG10483 Thal (PI) 9/1/02-9/1/07  
 NIH/NIA/ADCS Sano (Project director)  
 A multi-center, randomized, double-blind, placebo-controlled trial of simvastatin to slow the progression of Alzheimer's disease.  
 This study is to determine the safety and efficacy of simvastatin in slowing the progression of Alzheimer's disease. (Phase III)  
 Role: Site PI
35. #EFC2946 9/1/04-1/29/07  
 Sanofi-Synthelabo Research  
 A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of xaliproden in patients with mild-to-moderate dementia of the Alzheimer's type.  
 This study is to determine safety and efficacy of xaliproden for the treatment of Alzheimer's disease. (Phase III)  
 Role: Site PI
36. MNI-187-01 Jennings (PI) 11/01/07-1/7/09  
 Institute for Neurodegenerative Disorders  
 Validation of Imaging Evaluations in Individuals With Alzheimer's Disease and Healthy Subjects (VIEW-AD; Phase 1)  
 This study is to evaluate multiple imaging markers for Alzheimer disease and identify SPECT ligands that most clearly distinguish Alzheimer's disease from healthy subjects of similar age. Phase 2 will consist of a multi-site imaging study of the most promising ligand(s).  
 Role: Site PI
37. U01 #AG10483 Thal (PI) 8/10/03-1/30/09  
 NIH/NIA/ADCS Tariot (Project director)  
 A randomized, double-blind, placebo-controlled trial of valproate to attenuate the progression of Alzheimer's disease.  
 This study is to determine the efficacy of valproate in preventing or delaying the emergence of agitation in patients with Alzheimer's disease. (Phase III)  
 Role: Site PI
38. U01 #AG10483 Thal (PI) 1/01/07- 5/31/09  
 NIH/NIA/ADCS Quinn (Project director)  
 Effects of Docosahexaenoic Acid (DHA) in slowing the progression of Alzheimer's disease.  
 This study is to determine the efficacy of DHA slowing the progression of cognitive and functional decline over 18 months in patients with mild to moderate Alzheimer's disease. (Phase III)  
 Role: Site PI
39. B0401005 08/14/09-2010  
 Pfizer  
 A phase 2 multicenter, double-blind placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer's disease (Phase II)  
 This study is to determine safety and potential efficacy of PF-04447943 for the treatment of mild to moderate Alzheimer's disease.  
 Role: Site PI



47. 1R01 #NR010559-01 Tremont (PI) 9/28/07-5/31/13  
NIH/NINR  
Psychosocial telephone intervention for dementia caregivers  
This study is to determine the efficacy of a telephone-based, psychosocial intervention to improve caregiver burden and depression in dementia caregivers.  
Role: Co-Investigator (5%)
48. #160701 Aisen (PI) 1/14/09-12/31/13  
ADCS/Baxter Relkin (Project Director)  
A randomized, double-blind, placebo-controlled, two dose-arm, parallel study of the safety and effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of mild-to-moderate Alzheimer's disease  
This study is to determine safety and efficacy of IGIV for the treatment of Alzheimer's disease. (Phase III)  
Role: Site PI
49. Rhode Island Hospital Ott (PI) 9/01/11-10/31/13  
Video intervention for the safety of cognitively impaired older drivers.  
This pilot study is to examine the effects of a video event recorder intervention to enhance safe driving in people with questionable to mild dementia.  
Role: Principal Investigator
50. Rhode Island Hospital Cooper (PI) 2011-2014  
CAFÉ: Cognitive Assessment after Fracture in the Elderly.  
This study is to examine the effect of cognitive functioning and mental health on recovery from hip fracture.  
Role: Consultant
51. #F-AV-45-A18  
Avid Pharmaceuticals, Inc. 1/2/13-2014  
A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline. (Phase 4)  
Role: Site PI
52. 1 K08 HS017735-01 Daiello (PI) 6/1/09-12/31/14  
AHQR  
Neglected by the evidence: The intersection of medical complexity and dementia.  
This is a mentored clinical science project focusing on the impact of cholinesterase inhibitor and anesthetic agents on cognitively impaired elders with complex medical illness.  
Role: Mentor
53. Pfizer Snyder (PI) 3/01/13-2014  
Detection of disease-related changes in pre-symptomatic Alzheimer's disease.  
This study is to explore several new non-invasive technologies to assist in the identification of older adults who are in the pre-symptomatic phase of Alzheimer's disease. (Phase 1)  
Role: Coinvestigator
54. American Heart Association Alosco (PI) 2013-2015  
Cognitive impairment and driving performance in heart failure.  
Predoctoral Fellowship  
Role: Collaborator and Mentor
55. #BP2848  
F. Hoffmann-La Roche, Ltd. 1/2/13- 2014  
A multicenter, randomized, double-blind, parallel-group placebo-controlled study to investigate the efficacy and safety of RO4602522 versus placebo, used as adjunctive treatment to the acetylcholinesterase inhibitors donepezil,

galantamine or rivastigmine in patients with moderately severe Alzheimer's disease. (Phase 2B)  
This study is to examine safety and efficacy a MAO-B inhibitor in patients with moderate stage Alzheimer's disease.

Role: Site PI

56. #H8A-MC-LZAX

Eli Lilly and Company

06/24/2013-2016

Effect of solanezumab (LY20624340), an anti-amyloid beta monoclonal antibody, on the progression of Alzheimer's disease as compared with placebo. (EXPEDITION 3 study). (Phase 3)

This study is to examine the safety, efficacy and tolerability of solanezumab in slowing the cognitive decline of mild Alzheimer's disease.

Role: Site PI

57. #TRx-237-005

TauRx Therapeutics Ltd.

07/09/2013-2016

Randomized, double-blind, placebo-controlled, parallel-group, 18-month safety and efficacy study of Leuco-methylthionium bis(hydromethanesulfonate) in subjects with mild Alzheimer's disease. (Phase 3)

This study is to examine the safety, efficacy and tolerability of Leuco-methylthionium in the treatment of mild Alzheimer's disease. (Phase 3)

Role: Site PI

58. #221AD103

Biogen Idec MA, Inc.

1/6/13-2015

A randomized, double-blind, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer's disease. (Phase 1B)

This study is to examine safety, tolerability, pharmacokinetics, and pharmacodynamics of a biological agent against beta amyloid in patients with early Alzheimer's disease.

Role: Site PI

59. Canadian Institute of Health Research

6/2015 – 4/2016

A collaborative international knowledge synthesis to update guidelines for determining medical fitness to operate motor vehicles.

This study is to create a knowledge synthesis and clinical guidelines on driving risks: traumatic brain injury and dementia.

Role: Project expert

60. AC-1204

Accera, Inc.

12/-01/13-2016

26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD study). (Phase 4).

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.

Role: Data safety monitoring board member

61. #1R03AG046472-01

Ott (PI)

9/15/2014-8/31/2016

NIH/NIA

Secondary analyses and archive of naturalistic driving data in aging and dementia.

This study is to analyze naturalistic driving data obtained from older drivers with and without dementia using advanced GPS and computerized video programs that will result in a rich dataset that can then be compared to data obtained from standardized on-road tests in the same individuals.

Role: Principal investigator (8%)

62. #MK-8931-017  
Merck Sharp & Dohme Corp. 06/13/13-02/14/17  
A Phase III, randomized, placebo-controlled, parallel-group, double-blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease. (Phase 2/3)  
This study is to examine the safety, efficacy and tolerability of MK-8931 in the treatment of mild to moderate Alzheimer's disease.  
Role: Site PI
63. Nation's Carelink/Univita/LTCG Ott (PI) 10/01/06-9/30/17  
Telephone screening for mild cognitive impairment.  
This study is to determine the sensitivity and specificity of the Minnesota Cognitive Acuity Screen (MCAS) for mild cognitive impairment.  
Role: PI
64. #18F-AV-1451-A05  
Avid Radiopharmaceuticals, Inc. 1/25/14-2017  
An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with mild cognitive impairment, and subjects with Alzheimer's disease. (Phase 2)  
This study is to compare 18F-AV-1451 imaging results in subjects with Alzheimer's disease to subjects with mild cognitive impairment and cognitively healthy older individuals and to establish a database of cognitively healthy individuals to show the spectrum of 18F-AV-1451 imaging results in cognitively healthy individuals across a range of age strata.  
Role: Site PI
65. #20130385 4/2/2015- 2017  
Amgen, Inc.  
A double-blind, placebo controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid lowering therapy: A study for subjects enrolled in the FOURIER trial. Evaluating PCSK9 Binding antiBody Influence on coGnitive HeAlth in High cardiovasUlar Risk Subjects (EBBINGHAUS study).  
This study evaluates change over time in neurocognitive testing in subjects receiving statin therapy in combination with evolocumab (AMG 145), compared with subjects receiving statin therapy in combination with placebo.  
Role: Steering committee member
66. Rhode Island Hospital Ott (PI) 2/1/16 – 6/30/17  
Neurology Department  
Pilot study of repetitive transcranial magnetic stimulation (rTMS) in the treatment of frontotemporal dementia.  
This study is to determine if there is evidence of acute symptomatic cognitive benefits for rTMS when administered to patients with behavioral and progressive aphasia variants of frontotemporal dementia.  
Role: Principal investigator
67. NIH/NIA 2U01 AG024904-06 Weiner (PI) 09/30/04 – 09/15/16  
NIH/NIA/ADCS Petersen and Aisen (Protocol directors)  
The Alzheimer's disease neuroimaging initiative 1, and 2.  
This study is to develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on persons with Alzheimer's disease, mild cognitive impairment, and normal elderly.  
Role: Site PI

68. Alzheimer's Association Rabinovici (Study Chair) 4/6/2015 – 12/7/17  
 CMS/ACR/ACRIN  
 The Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study  
 This study of patients receiving amyloid PET scan diagnostic test results for possible Alzheimer's disease seeks to understand the influence of having a positive test result on decisions to seek additional diagnostic testing or treatment and the potential cost benefits.  
 Role: Site PI
69. Rhode Island Foundation Ott (PI) 12/26/16 – 12/25/17  
 Building the Rhode Island Alzheimer's Disease Prevention Registry  
 This grant is to support personnel, advertising and printing costs for expansion of the Rhode Island Alzheimer's Disease Prevention Registry, including outreach to minorities and primary care physicians.  
 Role: PI
70. #MK-8931-019 Merck Sharp & Dohme Corp. 06/13/14 – 01/22/2018  
 A randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK-8931 in subjects with amnesic mild cognitive impairment due to Alzheimer's disease. (Phase 3)  
 This study is to examine the safety, efficacy and tolerability of MK-8931 in the treatment of mild cognitive impairment due to Alzheimer's disease.  
 Role: Site PI
71. 5U01 #AG10483-21 Aisen (PI) 07/01/11 – 5/31/2018  
 NIH/NIA/ADCS/Univita/LTCG Ott (Sub-Project director)  
 ADCS Infrastructure Support: Rhode Island Alzheimer Prevention Registry.  
 This sub-project is to identify potential volunteers who would be willing to participate in upcoming early intervention and prevention trials under the sponsorship of the ADCS  
 Role: Site PI
72. #ADC-046-INI NIH/NIA/ADCS Craft (PI) 11/01/13 – 12/31/18  
 Therapeutic effects of intranasally administered insulin in adults with amnesic mild cognitive impairment or mild Alzheimer's disease. (SNIFF study). (Phase 2/3)  
 This study is to examine the effects of intranasally administered insulin on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid biomarkers in amnesic mild cognitive impairment or mild Alzheimer's disease.  
 Role: Site PI
73. #I8D-MC-AZET Eli Lilly & Co. 11/14/16 – 6/11/2018  
 Randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in mild Alzheimer's disease dementia (The DAYBREAK Study). (Phase 2/3)  
 This study is to test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD as compared with placebo in patients with mild AD dementia.  
 Role: Site PI
74. #54861911ALZ2003 Sperling (PI) 12/30/16 – 6/11/18  
 USC Alzheimer Therapeutic Research Institute/Janssen Research and Development, LLC  
 A randomized, double-blind, placebo-controlled, parallel group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer's dementia. (Phase 2b/3) (The EARLY Study)  
 This study is to investigate the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer's dementia.  
 Role: Site PI

75. #ADC-040-A4 Aisen (PI)  
 NIH/NIA/ADCS Sperling (Project Director) 12/01/13 – 2/29/2020  
 Anti-amyloid treatment in asymptomatic Alzheimer’s disease (A4 Study). (Phase 3)  
 This study is to determine if solanezumab, administered as an intravenous infusion at a dose of 400 mg every 4 weeks for 3 years, will slow cognitive decline as compared with placebo in subjects with preclinical Alzheimer’s disease.  
 Role: Site PI
76. # AG0045058 Obisesan (PI) 07/10/17 – 6/30/2020  
 NIH/NIA  
 Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach.  
 Role: Data safety monitoring board member
77. #221AD302 07/01/15 – 3/2019  
 Biogen MA Inc.  
 A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. (EMERGE study)  
 This study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment in subjects with early Alzheimer’s disease.  
 Role: Site PI
78. #NPSASA-15-363629 Tremont (PI) 9/1/15 – 10/31/19  
 Alzheimer’s Association  
 Pilot trial of a mind-body intervention for mild cognitive impairment.  
 This study is to determine the preliminary efficacy of a yoga intervention for improving cognition, quality of life/emotional function, and daily living skills in individuals with mild cognitive impairment compared to the control, healthy living education.  
 Role: Co-investigator (3%)
79. #NPSASA-15-362133 Ott (PI) 9/1/15 – 10/31/19  
 Alzheimer’s Association  
 Video feedback intervention for cognitively impaired older drivers.  
 This study is to determine the efficacy of a video feedback intervention for reducing unsafe driving event frequency in older individuals with mild cognitive impairment and early Alzheimer’s disease compared to passive monitoring.  
 Role: Principal investigator (6%)
80. Seed Grant Heindel (PI) 3/1/18 – 2/28/20  
 Brown University  
 Combined EEG and pupilometry measures of language processing as markers for early detection of Alzheimer’s disease  
 This study exploits recent advances in cognitive neuroscience to develop novel probes that are sensitive to both the earliest cognitive changes in AD and the compensatory processes moderating these changes, and that can be utilized as a neurocognitive “stress test” for early detection of AD.  
 Role: Co-Investigator
81. Rhode Island Foundation Ott (PI) 7/1/18 – 6/30/19  
 Confronting Alzheimer’s: Primary Care and Registry Partnership Program  
 This project is to screen aging Rhode Islanders at risk for Alzheimer’s disease and offer them ways to optimize their cognitive health through education and risk factor reduction, by partnering with primary care physicians in Rhode Island.  
 Role: Principal Investigator

82. Global Alzheimer's Platform Foundation Ott (PI) 7/1/18 – 10/31/19  
 This is an infrastructure grant to support recruitment and enrollment into Alzheimer's disease prevention and treatment clinical trials.  
 Role: Principal Investigator
83. 1R56AG053934-01 Mor (PI) 9/1/17 – 8/31/20  
 NIH/NIA  
 Caregivers' reactions and experience: Imaging dementia evidence for amyloid scanning (CARE-IDEAS)  
 This study will fill important gaps in our understanding of how informal caregivers and patients react to the results of Amyloid PET scans as part of the IDEAS study.  
 Role: Consultant
84. #3P20GM119943-03S1 Quesenberry (PI) 7/1/2019-6/30/2020  
 NIH/NIGMS  
 Retrotransposable element expression in neural stem cell senescence and aging.  
 This supplemental study is to examine salivary extracellular vesicles and their role in Alzheimer's disease.  
 Role: Co-investigator (2%)
85. Rhode Island Foundation Ott (PI) 10/1/19-9/30/2020  
 Development of a web-based cognitive screening instrument.  
 The goal of this project is to design, develop, and validate a self-administered web-based cognitive screening application for use in the primary care setting as well as the Rhode Island Alzheimer Prevention Registry.  
 Role: Principal Investigator
86. #I5T-MC-AACG 11/2/17 – 2021  
 Eli Lilly and Company  
 Assessment of safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic Alzheimer's disease (The TRAILBLAZER Study). (Phase 3)  
 This study is to assess the safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic Alzheimer's disease.  
 Role: Site PI
87. Rhode Island Foundation Ott (PI) 10/1/20-9/30/2021  
 Validation of a self-administered, tablet based memory test  
 The goal of this project is to validate a self-administered web-based cognitive screening application for use in the primary care setting as well as the Rhode Island Alzheimer Prevention Registry.  
 Role: Principal Investigator
88. #LEARN-15-338730 Aisen (PI) 1/01/16 – 2021  
 USC/Alzheimer's Association Sperling (Project Director)  
 Anti-amyloid treatment in asymptomatic Alzheimer's disease (A4 Study). (Phase 3)  
 This study is to determine the natural history of cognitive change in older people who lack amyloid on PET imaging.  
 Role: Site PI
89. #R01AG056466 Roe (PI) 8/1/17 – 5/31/22  
 NIH/NIA  
 Preclinical Alzheimer's disease and driving  
 This study is to examine biomarkers of Alzheimer's disease as predictors of driving impairment in the preclinical stage of Alzheimer's disease.  
 Role: Consultant

90. #M15-566 01/02/17 – 2021  
 AbbVie  
 A phase 2 multiple dose, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer’s disease (The AWARE Study). (Phase 2)  
 This study is to assess the efficacy of ABBV-8E12 in slowing disease progression (cognitive and functional impairment) in subjects with early AD as measured by the CDR-SB and to assess long term efficacy for up to 96 weeks.  
 Role: Site PI
91. NIH/NIA U19AG024904 Weiner (PI) 09/15/16 - 7/31/21  
 NIH/NIA/ADCS Petersen and Aisen (Protocol directors)  
 The Alzheimer’s Disease Neuroimaging Initiative 3.  
 This study is to develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on persons with Alzheimer’s disease, mild cognitive impairment, and normal elderly.  
 Role: Site PI
92. BHV4157-203 Feldman (PI) 1/9/18 – 2021  
 ADCS/ Pharmaceuticals Holding Co. Ltd.  
 A seamless phase 2A-B randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of BHV-4157 in patients with mild to moderate Alzheimer’s disease (The T2PROTECT AD study). (Phase 2A-B)  
 This study is to assess the safety, tolerability and efficacy of BHV-4157 in mild to moderate Alzheimer’s disease.  
 Role: Site co-PI
93. #251AD201 6/1/18 – 9/8/21  
 Biogen MA Inc.  
 Randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, and efficacy of BIIB092 in subjects with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease (The TANGO study). (Phase 2)  
 This study is to assess the safety, tolerability and efficacy of BIIB092 in early symptomatic Alzheimer’s disease.  
 Role: Site PI
94. #R01AG058648 Daiello (PI) 4/1/2019-3/31/2024  
 NIH/NIA  
 Blood-brain barrier disruption as a biomarker for perioperative neurocognitive disorder: Cognitive recovery after elective surgery.  
 This study is to analyze blood-brain barrier disruption as a biomarker for the development of perioperative neurocognitive disorders after elective surgery in older adults.  
 Role: Co-investigator (2%)
95. 1R21AG064410 Tremont (PI) 6/1/19-5/31/2021  
 NIH/NIA  
 Translating a dementia caregiver intervention into a mobile application.  
 The goal of this project is to adapt and test the Family Intervention: Telephone Tracking Caregiver intervention for a mobile device.  
 Role: Co-investigator (2%)
96. 5R01 AG053798-02 Aisen (PI) 5/1/19-12/3/2022  
 Global Alzheimer’s Platform trial-ready cohort for preclinical/prodromal Alzheimer’s disease.  
 This project aims to accelerate current and future secondary prevention trial enrollment through an innovative, highly efficient approach to identify, evaluate, and enroll appropriate preclinical and prodromal trial candidates, supported by a new site network with enhanced capacities for more efficient and effective conduct of AD clinical trials (The TRC-PAD Study)  
 Role: Site PI

97. #5R01AG059613-02 Betz (PI) 05/01/19 – 02/29/24  
NIH/NIA  
Decision making among older adults: The AUTO study.  
This study aims to test the efficacy of a Driving Decision Aid in improving decision quality, determine its effects in specific subpopulations of older adults, including individuals with early Alzheimer’s disease and/or mild cognitive impairment, and identify the best settings for its future use.  
Role: Data safety monitoring board chair
97. #BAN2401-G000-301 12/1/19 – 2022  
Eisai, Inc.  
A placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer’s disease. (The CLARITY Study) (Phase 3)  
This study is to assess the safety, tolerability and efficacy of BAN2401 in early symptomatic Alzheimer’s disease.  
Role: Site Co-investigator
98. 1R01AG061848-01 Aisen (PI) 9/30/19 - 05/31/2024  
NIH/NIA and Eisai  
A Placebo-Controlled, Double Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment with BAN2401 in Subjects with Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects with Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial).”(The AHEAD Study). (Phase 3)  
This study is to assess the efficacy, safety and tolerability of BAN2401 in reducing cognitive decline and brain amyloid accumulation in people with preclinical Alzheimer’s disease.  
Role: Site Co-investigator
99. 1 R01 AG065722-02 Zullo (PI) 10/1/20 – 9/30/2024  
NIH/NIA  
Medications and the risk of motor vehicle crashes in older drivers.  
The objective of this project is to evaluate the effects of medications, including dose and adherence, on motor vehicle crashes in older adults.  
Role: Co-investigator (2%)
100. 1 R01 AG068450-01 Alkusky (PI) 9/1/20 – 8/31/2023  
NIH/NIA  
Antidementia medication use, safety, and effectiveness among nursing home residents with Alzheimer’s disease. The objective of this project is to examine contemporary patterns of cholinesterase inhibitor and memantine use in nursing home residents with Alzheimer’s disease, comparing long-term effectiveness and safety outcomes.  
Role: Co-investigator (10%)
101. #221AD304 4/1/20 – 2021  
Biogen MA Inc.  
Phase 3b open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. (The EMBARK study) (Phase 3b)  
This open label study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer’s disease who were actively participating in prior aducanumab clinical trials.  
Role: Site Co- investigator
102. #LX1001.O1 3/12/21- 2022  
Lexeo Therapeutics/Watermark  
A 52-Week, Multicenter, Phase I Open-label Study to Evaluate the Safety ofLX1001 in Patients with APOE4 Homozygote Alzheimer's Disease. (The LEAD Study) (Phase 1)  
This is an open label, dose-ranging study to evaluate gene therapy for patients who are APOE4 homozygotes with clinical diagnoses varying from MCI to mild or moderate dementia due to Alzheimer’s disease.

Role: DSMB member

103. 1 R41 AG074835-01  
NIH/NIA

Mankodiya (PI)

7/1/21-6/30/22 (pending)

Development of a digital cognitive screening test to detect mild cognitive impairment and dementia in clinical settings.

This STTR Phase 1 project aims to develop and test an innovative digital cognitive screening instrument to identify mild cognitive impairment and dementia in older adults.

Role: Coinvestigator (5%)

UNIVERSITY TEACHING ROLES:

1984-1985      Introductory lectures to Harvard medical students on neurology rotation, Brigham & Women's Hospital

1989-1996      BioMed 301 *Clerkship in Internal Medicine*

Introductory lectures and group case discussions in neurology for third year Brown medical students rotating on medical clerkship, Roger Williams Medical Center

One session every three months, 1989-1995

Outpatient general neurology clerkship. One student every other month for one afternoon each week, 1995-1996

1989-2005      BioMed 304F *Clerkship in Consultative Neurology*

Clinical teaching rotation for medical students, Roger Williams Medical Center and Memorial Hospital

1990-2006      BioMed 262 *Neurosciences Pathophysiology* lectures

Revised and improved syllabus and presented lectures.  
Toxic and Metabolic Disorders of the CNS

Instituted new syllabus and presented lectures.  
Infections of the CNS

Revised and improved syllabus and presented lectures.  
Aging and Dementia

1990-2006      BioMed 262 *Neurosciences Pathophysiology* Small Group Laboratory Session leader

Four to five sessions each year, 10-12 students

1993              With assistance of Dr. Sydney Louis, designed and produced a self study and assessment computer program in *Behavioral Neurology* for medical students and housestaff.

1993-2005      BioMed 315F *Clerkship in Adult Ambulatory Medicine (Neurology)*

For Brown medical students, Roger Williams Medical Center and Memorial Hospital.  
One half-day weekly over six months with one student in general neurology outpatient practice setting

1998-2005      Clerkship leader

1993-              Clinical supervisor for graduate student research projects in dementia, Brown University

Department of Psychology, at Roger Williams, Memorial and Rhode Island Hospitals

1994 Independent *Clerkship in Advanced Physical Diagnosis* for third year Brown medical student

1994- Instituted new syllabi and presented lectures for University of Rhode Island courses  
 PHP 561/562: *Advanced Human Pathophysiology I and II*  
 PHP/BPS 312: *Foundations of Human Disease I and II*  
 PHP/BPS 310: *Foundations of Cardiovascular and Renal Disease*  
 PHP/BPS 412: *Foundations of CNS and Musculoskeletal Disease*

Pathophysiology of Pain

Aging and Dementia

Stroke: Ischemic and Hemorrhagic

1995 Brown University Summer FOCUS Program course, *So You Think You Want to be a Doctor: An Introduction to Medicine*, lecture to high school students

The Neurological Examination

1997-2005 BioMed 373-374 *Introduction to Clinical Medicine* lecture to second year Brown medical students  
 The Neurological Examination

1998-2000 University of Rhode Island Pharmacy Program course, *Advanced Human Pathophysiology for Practitioners* lectures

Pathophysiology of Pain

Alzheimer's Disease

Cerebrovascular Disease

1998- Website administrator, Department of Neurology, Brown University

2005 BioMed 372 *Epidemiology for the Practice of Medicine* small group laboratory leader

2007 Brown University PHP 2210 *Epidemiology of Chronic Disease*

Alzheimer's Disease lecture and discussion session

2008-2016 BIOL 903 *So You Want To Be a Doctor*

Case and career discussions; office shadowing experience: High school seniors

2010- BIOL 3790 *Aging and Dementia* elective for fourth year medical students, faculty member  
 2010-2018 Course leader

2011- BIOL 3795 *Clerkship in Neurology*, faculty member  
 2011-2012 Clerkship development working group leader

2012-2015 Roger Williams University Law School: *Planning for the Elderly Client* and *Introduction to Elder Law* courses  
Lecture and discussion session

HOSPITAL TEACHING ROLES:

1989-2005 Two month required clinical rotation in consultative neurology for first year psychiatry residents from Butler Hospital, at Roger Williams Hospital & Memorial Hospitals.

1989-2005 Noon lectures, consultation rounds, and neurology elective for medical housestaff, one out of every two to three months, Roger Williams and Memorial Hospitals.

1990- Alzheimer's disease and memory disorders specialty outpatient teaching clinic for PGY2 and PGY3 neurology residents, one morning per week year round, Roger Williams, Memorial, and Rhode Island Hospitals

1990-2005 Supervisor/mentor, two month required clinical rotation in consultative neurology for third year neurology residents, Roger Williams & Memorial Hospitals.

1990- Mentor, Neurology Residency Training Program, Rhode Island Hospital  
1990-1993 Ann Hake, MD  
2010-2013 Sergio Lanata, MD  
2016-2017 Timothy Steinhoff, MD

1992-1995 Workshop and journal club lectures in dementia diagnosis and treatment to psychiatry residents at Butler Hospital.

1993-1999 Internal Medicine Board Examination Review in Neurology for third year medical residents, Roger Williams & Memorial Hospitals. Three hour neurology review session, annual.

1994-1996 Director of Neurology Education for the Roger Williams Hospital Internal Medicine Residency. Compiled curriculum for neurology education, 1994.

1996-2005 Lectures and weekly case discussions for internal medicine residents, family practice residents, and Brown medical students, Memorial Hospital

1997- Organizer for monthly Aging and Dementia Research Seminar Series  
1998 -- Sponsored by the Alzheimer's Disease & Memory Disorders Center  
2012 -- Co-sponsored by the Norman Prince Neurosciences Institute Aging Brain Initiative

1998-2013 Supervisor/mentor, memory disorder clinic outpatient teaching rotation for Brown University Geriatric Psychiatry Fellowship Training Program

1999- Internship faculty member, Brown University Clinical Psychology Training Consortium  
2004- Research supervisor

2000- Supervisor/mentor, memory disorder clinic outpatient teaching rotation for Brown University Geriatric Medicine Fellowship Training Program

2001-2003 F-32 research fellowship co-sponsor (Rebecca Reddy, PhD)

2001-2008 Steering committee member, mentor, and lecturer for the Brown University T-32 Dementia Research Fellowship program

2003-2004	Director and mentor, Brown University Geriatric Neurology Fellowship (Anelyssa D'abreu, MD)
2005-2019	Teaching attending 1-2 months per year, ward and consultation services, for neurology and medical housestaff and medical students, Rhode Island Hospital.
2009-2014	K-08 research career award primary mentor (Lori Daiello, PharmD)
2013-2015	Predoctoral Fellowship award mentor (Michael Alosco, PhD)
2020-2025	K-23 research career award mentor (Laura Korthauer, PhD)
2015-	Director, Rhode Island Hospital and Brown University Aging and Dementia Fellowship
2016-2018	Seth Margolis, PhD
2017-2018	Jonathan Drake, MD
2018-2020	Laura Korthauer, PhD
2020-2021	Jamie Bass, DO
2020-2022	Deirdre O'Shea, PhD